| Year |
Citation |
Score |
| 2022 |
McLemore AF, Hou HA, Meyer BS, Lam NB, Ward GA, Aldrich AL, Rodrigues MA, Vedder A, Zhang L, Padron E, Vincelette ND, Sallman DA, Abdel-Wahab O, List AF, McGraw KL. Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS-STING-NLRP3 axis in Myelodysplastic syndromes. Jci Insight. PMID 35788117 DOI: 10.1172/jci.insight.159430 |
0.616 |
|
| 2022 |
Shin TH, Zhou Y, Chen S, Cordes S, Grice MZ, Fan X, Lee BC, AlJanahi AA, Hong SG, Vaughan KL, Mattison JA, Kohama SG, Fabre MA, Uchida N, Demirci S, ... ... List AF, et al. Macaque Clonal Hematopoiesis Model Demonstrates Expansion of TET2-Disrupted Clones and Utility for Testing Interventions. Blood. PMID 35714307 DOI: 10.1182/blood.2021014875 |
0.577 |
|
| 2021 |
Wang C, McGraw KL, McLemore AF, Komrokji R, Basiorka AA, Al Ali N, Lancet JE, Padron E, Kosmider O, Fontenay M, Fenaux P, List AF, Sallman DA. Dual pyroptotic biomarkers predict erythroid response in lower risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin. Haematologica. PMID 34320786 DOI: 10.3324/haematol.2021.278855 |
0.621 |
|
| 2021 |
Ward GA, McGraw KL, Abbas-Aghababazadeh F, Meyer BS, McLemore AF, Vincelette ND, Lam NB, Aldrich AL, Al Ali NH, Padron E, Pinilla-Ibarz J, Masala E, Santini V, Kosmider O, Fontenay M, ... ... List AF, et al. Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes. Blood Advances. 5: 2216-2228. PMID 33890980 DOI: 10.1182/bloodadvances.2020003475 |
0.63 |
|
| 2021 |
Hunter AM, Komrokji RS, Yun S, Al Ali N, Chan O, Song J, Hussaini M, Talati C, Sweet KL, Lancet JE, Padron E, List AF, Sallman DA. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes. Blood Advances. 5: 1017-1028. PMID 33591325 DOI: 10.1182/bloodadvances.2020003508 |
0.32 |
|
| 2021 |
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, ... ... List AF, et al. Eprenetapopt (APR-246) and Azacitidine in -Mutant Myelodysplastic Syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002341. PMID 33449813 DOI: 10.1200/JCO.20.02341 |
0.616 |
|
| 2021 |
List AF, Sun Z, Verma A, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman JK, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar TR, Artz AS, Schiffer CA, et al. Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001691. PMID 33439748 DOI: 10.1200/JCO.20.01691 |
0.653 |
|
| 2020 |
Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Jenkins IC, Fang M, Huynh M, Kopecky KJ, List AF, Naru J, Radich JP, et al. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. Biomarker Research. 8: 29. PMID 32817791 DOI: 10.1186/S40364-020-00208-1 |
0.362 |
|
| 2020 |
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA, Sullivan A, Warren S, MacBeth KJ, Meggendorfer M, Haferlach T, Boettcher S, ... ... List AF, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. PMID 32730593 DOI: 10.1182/Blood.2020006158 |
0.68 |
|
| 2020 |
Yun S, Geyer SM, Komrokji RS, Al Ali NH, Song J, Hussaini M, Sweet KL, Lancet JE, List AF, Padron E, Sallman DA. Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML). Leukemia. PMID 32728186 DOI: 10.1038/S41375-020-0997-4 |
0.437 |
|
| 2020 |
Santini V, Fenaux P, Giagounidis A, Platzbecker U, List AF, Haferlach T, Zhong J, Wu C, Mavrommatis K, Beach CL, MacBeth KJ, Almeida A. Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients. Leukemia. PMID 32661294 DOI: 10.1038/S41375-020-0961-3 |
0.407 |
|
| 2020 |
Komrokji RS, Ali NA, Sallman D, Padron E, Lancet J, Sokol L, Varnadoe C, Burnette PK, List A. Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL). Leukemia. PMID 32565544 DOI: 10.1038/S41375-020-0928-4 |
0.315 |
|
| 2020 |
Duong VH, Al Ali N, Zhang L, Padron E, Sallman D, Lancet JE, List AF, Komrokji RS. A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failure. Leukemia & Lymphoma. 1-7. PMID 32306798 DOI: 10.1080/10428194.2020.1751841 |
0.413 |
|
| 2020 |
Sallman DA, Barnard J, Al Ali NH, Garcia-Manero G, Sekeres MA, DeZern A, Steensma DP, Roboz G, Jabbour E, Maciejewski JP, Pierce S, Padron E, Lancet JE, Kantarjian H, List AF, et al. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities. Clinical Lymphoma, Myeloma & Leukemia. PMID 32303488 DOI: 10.1016/J.Clml.2020.03.005 |
0.363 |
|
| 2020 |
Martinez-Høyer S, Deng Y, Parker J, Jiang J, Mo A, Docking TR, Gharaee N, Li J, Umlandt P, Fuller M, Jädersten M, Kulasekararaj A, Malcovati L, List AF, Hellström-Lindberg E, et al. Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome. Nature Cell Biology. PMID 32251398 DOI: 10.1038/S41556-020-0497-9 |
0.399 |
|
| 2020 |
Michelson AP, McDonough S, Willman CL, Koegle ER, Godwin JE, Petersdorf SH, List AF, Othus M, Appelbaum FR, Radich JP, Ganapathi MK, Advani AS, Ganapathi RN. Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia. Scientific Reports. 10: 5486. PMID 32218491 DOI: 10.1038/S41598-020-62345-9 |
0.367 |
|
| 2020 |
Zhang Q, Haider M, Al Ali NH, Lancet JE, Epling-Burnette PK, List AF, Padron E, Komrokji RS. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia. PMID 32179032 DOI: 10.1016/J.Clml.2019.12.023 |
0.372 |
|
| 2020 |
Nguyen L, Zhang X, Roberts E, Yun S, McGraw K, Abraham I, Song J, Braswell D, Qin D, Sallman DA, Lancet JE, List AF, Moscinski LC, Padron E, Zhang L. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated versus acute myeloid leukemia with myelodysplasia-related changes with mutated . Leukemia & Lymphoma. 1-11. PMID 32091281 DOI: 10.1080/10428194.2020.1723016 |
0.676 |
|
| 2020 |
Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, Sweet K, Lancet J, List A, Bennett JM, Komrokji R. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia. PMID 32044274 DOI: 10.1016/J.Clml.2020.01.003 |
0.347 |
|
| 2020 |
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, ... ... List AF, et al. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. The New England Journal of Medicine. 382: 140-151. PMID 31914241 DOI: 10.1056/Nejmoa1908892 |
0.356 |
|
| 2020 |
Zeidan AM, Garcia-Manero G, Dezern AE, Fenaux P, Greenberg PL, Savona MR, Jurcic JG, Verma A, Mufti GJ, Buckstein R, Santini V, Laadem A, Zhang J, Rampersad A, Sinsimer D, ... ... List AF, et al. Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study. Journal of Clinical Oncology. 38: 7554-7554. DOI: 10.1200/Jco.2020.38.15_Suppl.7554 |
0.325 |
|
| 2020 |
Komrokji RS, Sekeres MA, Zeidan AM, Fenaux P, List AF, Dezern AE, Greenberg PL, Savona MR, Jurcic JG, Verma A, Mufti GJ, Buckstein R, Santini V, Laadem A, Ito R, et al. Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS). Journal of Clinical Oncology. 38: 7518-7518. DOI: 10.1200/Jco.2020.38.15_Suppl.7518 |
0.309 |
|
| 2020 |
Hashmi H, Lancet JE, Mishra A, Sweet K, Komrokji R, Fernandez H, Perez LE, Khimani F, Elmariah H, Pidala JA, Nieder ML, Bejanyan N, List AF, Anasetti C, Nishihori T. Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia – a Single Institution Experience Biology of Blood and Marrow Transplantation. 26. DOI: 10.1016/J.Bbmt.2019.12.623 |
0.395 |
|
| 2019 |
Melody M, Kuykendall A, Sallman D, Al Ali N, Zhang L, Talati C, Padron E, Sweet K, Extermann M, List A, Lancet J, Komrokji R. Defining Acute Myeloid Leukemia Ontogeny in Older Patients. Clinical Lymphoma, Myeloma & Leukemia. PMID 32139296 DOI: 10.1016/J.Clml.2019.11.007 |
0.366 |
|
| 2019 |
McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, ... ... List AF, et al. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. Blood Advances. 3: 3579-3589. PMID 31738830 DOI: 10.1182/Bloodadvances.2019000922 |
0.679 |
|
| 2019 |
Sweet K, Komrokji RS, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31636097 DOI: 10.1158/1078-0432.Ccr-19-2169 |
0.327 |
|
| 2019 |
Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leukemia Research. 84: 106194. PMID 31357093 DOI: 10.1016/J.Leukres.2019.106194 |
0.433 |
|
| 2019 |
Sundaravel S, Kuo WL, Jeong JJ, Choudhary GS, Gordon-Mitchell S, Liu H, Bhagat TD, McGraw KL, Gurbuxani S, List AF, Verma A, Wickrema A. Loss of function of DOCK4 in myelodysplastic syndromes stem cells is restored by inhibitors of DOCK4 signaling networks. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31308061 DOI: 10.1158/1078-0432.Ccr-19-0924 |
0.654 |
|
| 2019 |
Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leukemia Research. 81: 56-61. PMID 31030089 DOI: 10.1016/J.Leukres.2019.03.008 |
0.7 |
|
| 2019 |
Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, ... ... List AF, et al. Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis. Cancer Discovery. PMID 30944118 DOI: 10.1158/2159-8290.Cd-18-1138 |
0.627 |
|
| 2019 |
Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. PMID 30670444 DOI: 10.1182/Blood-2018-10-844654 |
0.337 |
|
| 2019 |
Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, ... ... List AF, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. PMID 30635634 DOI: 10.1038/S41375-018-0351-2 |
0.412 |
|
| 2019 |
Chan O, Hunter A, Talati C, Sallman DA, Asghari H, Song J, Hussaini M, Bejanyan N, Elmariah H, Kuykendall AT, Padron E, Komrokji RS, List AF, Lancet JE, Sweet KL, et al. Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation Blood. 134: 149-149. DOI: 10.1182/Blood-2019-131530 |
0.338 |
|
| 2019 |
Hunter AM, Ali NA, Sallman DA, Sweet KL, Kuykendall AT, Talati C, List AF, Lancet JE, Komrokji RS, Padron E. WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State Blood. 134: 1717-1717. DOI: 10.1182/Blood-2019-131071 |
0.337 |
|
| 2019 |
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore AF, McGraw K, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, ... ... List AF, et al. Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) Blood. 134: 676-676. DOI: 10.1182/Blood-2019-131055 |
0.644 |
|
| 2019 |
Chan O, Talati C, Asghari H, Bejanyan N, Elmariah H, Hussaini M, Khimani F, Kim J, Komrokji RS, Kuykendall AT, Lancet JE, List AF, Nieder M, Nishihori T, Padron E, et al. Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome Blood. 134: 4621-4621. DOI: 10.1182/Blood-2019-130922 |
0.358 |
|
| 2019 |
Asghari H, Lee D, Deutsch YE, Chan O, Ali NA, Boisclair S, Terrell C, Padron E, Kuykendall AT, List AF, Fernandez HF, Lancet JE, Sallman DA, Komrokji RS, Sweet KL, et al. Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia Blood. 134: 3895-3895. DOI: 10.1182/Blood-2019-130379 |
0.3 |
|
| 2019 |
Hunter AM, Ryan N, Hussaini M, Akabari R, List AF, Lancet J, Sallman DA, Komrokji RS, Ibarz JP, Kuykendall AT, Zhang L, Padron E. CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies Blood. 134: 4167-4167. DOI: 10.1182/Blood-2019-130196 |
0.305 |
|
| 2019 |
Chan O, Talati C, Asghari HH, Song J, Hussaini M, Kuykendall AT, Sallman DA, Padron E, Komrokji RS, List AF, Lancet JE, Mishra A, Sweet KL. RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation Blood. 134: 2052-2052. DOI: 10.1182/Blood-2019-129742 |
0.365 |
|
| 2019 |
Talati C, Caddell RJ, Tobon K, Komrokji RS, Kuykendall AT, Padron E, Fernandez HF, List AF, Sallman DA, Sweet KL, Lancet JE. Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia Blood. 134: 2636-2636. DOI: 10.1182/Blood-2019-129166 |
0.305 |
|
| 2019 |
Asghari H, Lee D, Deutsch YE, Chan O, Ali NA, Boisclair S, Brahim A, Padron E, Kuykendall AT, List AF, Fernandez HF, Lancet JE, Sallman DA, Komrokji RS, Sweet KL, et al. Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax Blood. 134: 1357-1357. DOI: 10.1182/Blood-2019-128958 |
0.355 |
|
| 2019 |
Balasis ME, Vedder A, Sun L, Quintana A, Dhawan A, Newman H, Merlevede J, McGraw K, Kruer T, Ben-Crentsil N, Painter JS, Droin N, Cluzeau T, Letson C, Wei S, ... ... List AF, et al. Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All-Trans retinoic Acid (ATRA) through the Transcription Factor CREB Blood. 134: 1692-1692. DOI: 10.1182/Blood-2019-128573 |
0.656 |
|
| 2019 |
Newman H, Hunter AM, Letson C, DeZern AE, Balasis ME, Dominguez-Viqueira W, Vedder A, Kruer T, Lancet JE, List AF, Roboz GJ, Steensma DP, Sekeres MA, Komrokji RS, Padron E. Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML) Blood. 134: 2984-2984. DOI: 10.1182/Blood-2019-128541 |
0.332 |
|
| 2019 |
Letson C, Vedder A, Quintana A, Liu P, Reid B, Balasis ME, Newman H, Kruer T, Almada LL, Zhang G, Fernandez-Zapico M, Patnaik MM, Lancet JE, Komrokji RS, Epling-Burnette P, ... List AF, et al. Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a Blood. 134: 4220-4220. DOI: 10.1182/Blood-2019-128165 |
0.332 |
|
| 2019 |
Zhang Y, Asghari HH, Chan O, Lee D, Extermann M, Ali NA, Deutsch YE, Padron E, Kuykendall AT, List AF, Fernandez HF, Lancet JE, Komrokji RS, Sallman DA, Talati C, et al. Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia Blood. 134: 1368-1368. DOI: 10.1182/Blood-2019-127772 |
0.326 |
|
| 2019 |
Lee D, Asghari HH, Deutsch YE, Chan O, Padron E, Kuykendall AT, List AF, Komrokji RS, Fernandez HF, Lancet JE, Sallman DA, Sweet KL, Talati C. CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia Blood. 134: 3894-3894. DOI: 10.1182/Blood-2019-127701 |
0.355 |
|
| 2019 |
Komrokji RS, Sallman DA, Ali NA, Kuykendall AT, Talati C, Sweet KL, Lancet JE, Padron E, List AF. SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome Blood. 134: 3001-3001. DOI: 10.1182/Blood-2019-127462 |
0.37 |
|
| 2019 |
List AF, Sun Z, Verma A, Bennett JM, McGraw K, Maciejewski JP, Komrokji RS, Wassenaar TR, Luger SM, Mattison RJ, Cheema PS, Altman JK, Claxton DF, Schiffer CA, Artz AS, et al. Combined Treatment with Lenalidomide and Epoetin Alfa Leads to Durable Responses in Patients with Epo-Refractory, Lower Risk Non-Deletion 5q [Del(5q)] MDS: Final Results of the E2905 Intergroup Phase III Study - an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health Blood. 134: 842-842. DOI: 10.1182/Blood-2019-127274 |
0.643 |
|
| 2019 |
Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Jenkins IC, Fang M, Huynh M, Kopecky KJ, List AF, Naru J, Radich JP, et al. Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report Blood. 134: 2691-2691. DOI: 10.1182/Blood-2019-124529 |
0.391 |
|
| 2019 |
Platzbecker U, Dunshee D, Komrokji RS, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Sekeres MA, See WL, Tsai K, Risueño A, Ma J, Schwickart M, Rampersad A, ... ... List AF, et al. Luspatercept Significantly Reduces Red Blood Cell (RBC) Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients (Pts) with LR-MDS Enrolled in the MEDALIST Trial Blood. 134: 2999-2999. DOI: 10.1182/Blood-2019-123655 |
0.358 |
|
| 2019 |
Fenaux P, Mufti GJ, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Komrokji RS, List AF, Zeidan AM, Verma A, Laadem A, Ito R, et al. Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions Blood. 134: 841-841. DOI: 10.1182/Blood-2019-123064 |
0.315 |
|
| 2019 |
Garcia-Manero G, Mufti GJ, Fenaux P, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, List AF, Laadem A, Ito R, Zhang J, Rampersad A, et al. Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions Blood. 134: 4243-4243. DOI: 10.1182/Blood-2019-123048 |
0.34 |
|
| 2019 |
Ward GA, McGraw K, McLemore AF, Lam NB, Hou H, Meyer BS, List AF. Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes Blood. 134: 774-774. DOI: 10.1182/Blood-2019-122358 |
0.629 |
|
| 2019 |
Ali NA, Sallman D, Nelson R, Talati C, Kuykendall A, Sweet K, Padron E, Lancet J, List A, Komrokji R. Venetoclax Combination with Hypomethylating Agents for Treatment of Myelodysplastic Syndromes Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.07.340 |
0.304 |
|
| 2019 |
Chan O, Jennings M, Asghari H, Song J, Hussaini M, Sallman D, Padron E, Komrokji R, List A, Lancet J, Mishra A, Sweet K, Talati C. RUNX1 Mutation is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia (AML) who Received Allogeneic Stem Cell Transplantation (allo-SCT) Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.07.119 |
0.37 |
|
| 2019 |
Jennings M, Chan O, Komrokji R, Padron E, Kuykendall A, List A, Mishra A, Lancet J, Sallman D, Sweet K, Talati C. Impact of the Number of Consolidation Chemotherapy Cycles Prior to Allogeneic Stem Cell Transplant for Adults with Acute Myeloid Leukemia in First Remission Clinical Lymphoma, Myeloma & Leukemia. 19. DOI: 10.1016/J.Clml.2019.07.098 |
0.305 |
|
| 2019 |
Yun S, Sharma R, Chan O, Vincelette N, Sallman D, Sweet K, Padron E, Komrokji R, Lancet J, Moscinski L, Cleveland J, List A, Zhang L. Clinical Significance of MYC Oncoprotein Expression on Survival Outcome in Secondary Acute Myeloid Leukemia (sAML) Clinical Lymphoma Myeloma and Leukemia. 19: S205-S206. DOI: 10.1016/J.Clml.2019.07.066 |
0.324 |
|
| 2018 |
Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF. A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia. PMID 30713125 DOI: 10.1016/J.Clml.2018.12.005 |
0.328 |
|
| 2018 |
Lee JH, List A, Sallman DA. Molecular Pathogenesis of Myelodysplastic Syndromes with deletion 5q. European Journal of Haematology. PMID 30578738 DOI: 10.1111/Ejh.13207 |
0.376 |
|
| 2018 |
Betts BC, Locke FL, Sagatys EM, Pidala J, Walton K, Menges M, Reff J, Saha A, Djeu JY, Kiluk JV, Lee MC, Kim J, Kang CW, Tang CA, Frieling J, ... ... List A, et al. Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. Frontiers in Immunology. 9: 2887. PMID 30574153 DOI: 10.3389/Fimmu.2018.02887 |
0.3 |
|
| 2018 |
Andrew K, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. American Journal of Hematology. PMID 30390311 DOI: 10.1002/Ajh.25335 |
0.385 |
|
| 2018 |
Sekeres MA, Swern AS, Giagounidis A, List AF, Selleslag D, Mittelman M, Schlegelberger B, Göhring G, Li JS, Sugrue MM, Fenaux P. The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q). Blood Cancer Journal. 8: 90. PMID 30291223 DOI: 10.1038/S41408-018-0126-Z |
0.369 |
|
| 2018 |
Talati C, Sallman D, List AF. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q. Clinical Lymphoma, Myeloma & Leukemia. PMID 30097406 DOI: 10.1016/J.Clml.2018.07.293 |
0.397 |
|
| 2018 |
Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, ... ... List AF, et al. Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study. The Lancet. Haematology. PMID 30072146 DOI: 10.1016/S2352-3026(18)30109-1 |
0.62 |
|
| 2018 |
List A, Ebert BL, Fenaux P. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion. Leukemia. 32: 1493-1499. PMID 29445113 DOI: 10.1038/S41375-018-0029-9 |
0.379 |
|
| 2018 |
Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR. Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). Leukemia Research. 67: 17-20. PMID 29407182 DOI: 10.1016/J.Leukres.2018.01.021 |
0.419 |
|
| 2018 |
McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes. British Journal of Haematology. PMID 29359794 DOI: 10.1111/Bjh.15099 |
0.621 |
|
| 2018 |
Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, ... ... List AF, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. The Lancet. Haematology. PMID 29331635 DOI: 10.1016/S2352-3026(18)30002-4 |
0.365 |
|
| 2018 |
Kubal TE, Salamanca C, Komrokji RS, Sallman DA, Sweet KL, Padron E, List AF, Lancet JE. Safety and feasibility of outpatient induction chemotherapy with CPX-351 in selected older adult patients with newly diagnosed AML. Journal of Clinical Oncology. 36: e19013-e19013. DOI: 10.1200/Jco.2018.36.15_Suppl.E19013 |
0.332 |
|
| 2018 |
Yun S, Sharma R, Sallman DA, Vincelette ND, Sweet KL, Padron E, Komrokji RS, Lancet JE, Moscinski LC, Cleveland J, List AF, Zhang L. Prognostic Impact of MYC Oncoprotein Expression on Survival Outcome in Secondary AML Patients Blood. 132: 2756-2756. DOI: 10.1182/Blood-2018-99-120048 |
0.46 |
|
| 2018 |
Sallman DA, DeZern AE, Steensma DP, Sweet KL, Cluzeau T, Sekeres MA, Garcia-Manero G, Roboz GJ, McLemore AF, McGraw KL, Puskas J, Zhang L, Bhagat CK, Yao J, Al Ali N, ... ... List AF, et al. Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Blood. 132: 3091-3091. DOI: 10.1182/Blood-2018-99-119990 |
0.67 |
|
| 2018 |
Talati C, Goldberg AD, Przespolewski A, Chan O, Ali NA, Famulare C, Sallman DA, Padron E, Kuykendall A, List AF, Lancet JE, Wang ES, Tallman MS, Komrokji RS, Sweet KL. Comparison of Induction Strategies and Responses for Acute Myeloid Leukemia Patients after Resistance to Hypomethylating Agents for Antecedent Myeloid Malignancy Blood. 132: 665-665. DOI: 10.1182/Blood-2018-99-119879 |
0.354 |
|
| 2018 |
McGraw KL, Cheng C, Chen YA, Hou H, Genovese G, Cluzeau T, Pellagatti A, Przychodzen B, Mallo M, Leonor A, Mohamedali AM, Ades L, Sallman DA, Padron E, Sokol L, ... ... List AF, et al. SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition Blood. 132: 107-107. DOI: 10.1182/Blood-2018-99-118747 |
0.673 |
|
| 2018 |
Ward GA, McGraw KL, McLemore AF, Abbas-Aghababazadeh F, Hou H, Trinh TL, Vincelette ND, Meyer BS, Onimus AH, Calescibetta A, Eksioglu EA, Wei S, List AF. Oxidized Mitochondrial DNA Is a Catalyst and Biomarker of Pyroptotic Cell Death in Myelodysplastic Syndromes Blood. 132: 3076-3076. DOI: 10.1182/Blood-2018-99-118493 |
0.651 |
|
| 2018 |
Shah S, Talati C, Ali NA, Padron E, Sallman DA, Sweet KL, Lancet JE, List AF, Komrokji RS, Kuykendall AT. Investigating Patient Characteristics and Outcomes of Myelofibrosis Patients with Hyperleukocytosis Blood. 132: 3041-3041. DOI: 10.1182/Blood-2018-99-117834 |
0.32 |
|
| 2018 |
Kuykendall AT, Talati C, Zhang L, Al Ali N, Sweet KL, Sallman DA, Lancet JE, List AF, Padron E, Komrokji RS. Genomic Characterization Provides Diagnostic Clarity in Cases with Overlapping Bone Marrow Fibrosis and Monocytosis Blood. 132: 4283-4283. DOI: 10.1182/Blood-2018-99-117796 |
0.344 |
|
| 2018 |
Talati C, Goldberg AD, Desai P, Chan O, Famulare C, Komrokji RS, Kuykendall AT, Fernandez HF, Deutsch YE, Padron E, List AF, Lancet JE, Roboz GJ, Tallman MS, Sallman DA, et al. Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia Blood. 132: 2741-2741. DOI: 10.1182/Blood-2018-99-117412 |
0.317 |
|
| 2018 |
McLemore AF, McGraw KL, Hou H, Ward GA, Onimus AH, Vincelette ND, Rodrigues MA, Chaudhary N, Zhang L, Meyer BS, Eksioglu EA, Wei S, List AF. Genomic-DNA Exposed By Somatic Gene Mutations Engages the cGAS/STING Axis to License the NLRP3 Inflammasome in Myelodysplastic Syndromes Blood. 132: 3075-3075. DOI: 10.1182/Blood-2018-99-116929 |
0.652 |
|
| 2018 |
Nazha A, Komrokji RS, Meggendorfer M, Mukherjee S, Ali NA, Walter W, Hutter S, Padron E, Madanat YF, Sallman DA, Kuzmanovic T, Hirsch CM, Adema V, Steensma DP, DeZern AE, ... ... List AF, et al. A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes Blood. 132: 793-793. DOI: 10.1182/Blood-2018-99-114774 |
0.386 |
|
| 2018 |
Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Diez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, ... ... List AF, et al. The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions Blood. 132: 1-1. DOI: 10.1182/Blood-2018-99-110805 |
0.349 |
|
| 2018 |
Melody M, Ali NA, Sallman DA, Padron E, List AF, Lancet JE, Komrokji RS. Lenalidomide Is Effective Treatment Option for Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis Blood. 132: 4383-4383. DOI: 10.1182/Blood-2018-99-110237 |
0.307 |
|
| 2018 |
Sallman DA, DeZern A, Sweet K, Steensma DP, Cluzeau T, Sekeres M, Garcia-Manero G, Roboz G, McLemore A, McGraw K, Puskas J, Zhang L, Bhagat C, Graber A, Ali NHA, ... ... List AF, et al. Abstract CT068: Phase Ib/II combination study of APR-246 and azacitidine (AZA) in patients with TP53 mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct068 |
0.664 |
|
| 2018 |
Melody M, Alu NA, Sallman D, Padron E, List A, Lancet J, Komrokji R. Lenalidomide is Effective Treatment Option for Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis Clinical Lymphoma, Myeloma & Leukemia. 18. DOI: 10.1016/J.Clml.2018.07.167 |
0.307 |
|
| 2018 |
Talati C, Kuykendall A, Ali NA, Kim J, Sehovic M, Sallman D, List AF, Komrokji R, Extermann M, Djulbegovic B, Sweet K, Lancet J. Hypomethylating Agents Versus Intensive Chemotherapy in Older Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count Clinical Lymphoma, Myeloma & Leukemia. 18. DOI: 10.1016/J.Clml.2018.07.051 |
0.352 |
|
| 2017 |
Mei Y, Zhao B, Basiorka AA, Yang J, Cao L, Zhang J, List A, Ji P. Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS. Leukemia. PMID 29263441 DOI: 10.1038/Leu.2017.326 |
0.32 |
|
| 2017 |
Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Annals of Hematology. PMID 29189896 DOI: 10.1007/S00277-017-3194-4 |
0.379 |
|
| 2017 |
Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Pogosov GL, Radich JP, Willman CL, Wood BL, et al. Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. Biopreservation and Biobanking. PMID 29172682 DOI: 10.1089/Bio.2017.0079 |
0.348 |
|
| 2017 |
Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS. The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes. Annals of Hematology. PMID 29167940 DOI: 10.1007/S00277-017-3186-4 |
0.433 |
|
| 2017 |
Sébert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Gyan E, Sanna A, Ali NH, Hobson S, Eclache V, List A, Fenaux P, Adès L. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leukemia Research. 63: 72-77. PMID 29112938 DOI: 10.1016/J.Leukres.2017.10.013 |
0.451 |
|
| 2017 |
Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia. PMID 29030092 DOI: 10.1016/J.Clml.2017.09.007 |
0.35 |
|
| 2017 |
Sallman DA, Tanaka TN, List A, Bejar R. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma & Leukemia. 17: 613-620. PMID 29025689 DOI: 10.1016/J.Clml.2017.09.018 |
0.386 |
|
| 2017 |
Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Maciejewski JP, Auberger P, Wei S, Fenaux P, Santini V, List A. Pro-inflammatory proteins S100A9 and TNFα suppress erythropoietin elaboration in myelodysplastic syndromes. Haematologica. PMID 28983059 DOI: 10.3324/Haematol.2016.158857 |
0.668 |
|
| 2017 |
Talati C, Sallman D, List A. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. Seminars in Hematology. 54: 159-166. PMID 28958290 DOI: 10.1053/J.Seminhematol.2017.06.003 |
0.377 |
|
| 2017 |
Zhang Q, Ball MC, Zhao Y, Balasis M, Letson C, Vedder A, List AF, Epling-Burnette PK, Komrokji RS, Padron E. Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia. Leukemia. PMID 28694526 DOI: 10.1038/Leu.2017.184 |
0.324 |
|
| 2017 |
Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, ... ... List A, et al. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma & Leukemia. PMID 28687222 DOI: 10.1016/J.Clml.2017.06.003 |
0.342 |
|
| 2017 |
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, ... ... List AF, et al. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). Journal of Hematology & Oncology. 10: 131. PMID 28651604 DOI: 10.1186/S13045-017-0491-2 |
0.402 |
|
| 2017 |
McGraw K, List A. Erythropoietin Receptor Signaling and Lipid Rafts. Vitamins and Hormones. 105: 79-100. PMID 28629526 DOI: 10.1016/Bs.Vh.2017.02.002 |
0.596 |
|
| 2017 |
Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, ... ... List AF, et al. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood. PMID 28576879 DOI: 10.1182/Blood-2017-01-763219 |
0.359 |
|
| 2017 |
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, et al. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2015662510. PMID 28486043 DOI: 10.1200/Jco.2015.66.2510 |
0.423 |
|
| 2017 |
Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma & Leukemia. PMID 28185797 DOI: 10.1016/J.Clml.2016.10.003 |
0.376 |
|
| 2017 |
Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E. Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis. Blood. PMID 28159734 DOI: 10.1182/Blood-2016-12-753210 |
0.304 |
|
| 2017 |
Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs. de novo myelodysplastic syndromes: A report on behalf of the MDS clinical research consortium. Leukemia. PMID 28111463 DOI: 10.1038/Leu.2017.33 |
0.376 |
|
| 2017 |
Cheng P, Eksioglu E, Chen X, Wei M, Guenot J, Fox J, List AF, Wei S. Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro Blood. 130: 51-51. DOI: 10.1182/Blood.V130.Suppl_1.51.51 |
0.346 |
|
| 2017 |
Nazha A, Patnaik MM, Komrokji RS, Al-Issa K, Daver N, Garcia-Manero G, Maciejewski JP, List AF, Savona MR, Itzykson R, Fenaux P, Santini V, Tefferi A, Sekeres MA, Padron E. Model Heterogeneity in Predicting Outcomes in Patients with Chronic Myelomonocytic Leukemia (CMML): An Overestimation of Survival in Lower-Risk Group Blood. 130: 4255-4255. DOI: 10.1182/Blood.V130.Suppl_1.4255.4255 |
0.309 |
|
| 2017 |
Sallman DA, Amy M, Komrokji RS, McGraw K, Geyer SM, Eksioglu E, Ali NA, Lancet JE, Wei S, Padron E, List AF. Immune Checkpoint Profiling of TP53 Mutant and Wild-Type Myeloid Malignancies: TP53 Mutations Direct Immune Tolerance Via an Immunosuppressive Phenotype Blood. 130: 423-423. DOI: 10.1182/Blood.V130.Suppl_1.423.423 |
0.687 |
|
| 2017 |
Shah S, Talati C, Ali NA, Padron E, Sallman DA, Sweet KL, Lancet JE, List AF, Zuckerman KS, Komrokji RS, Kuykendall A. Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis Blood. 130: 4186-4186. DOI: 10.1182/Blood.V130.Suppl_1.4186.4186 |
0.428 |
|
| 2017 |
Talati C, Kuykendall A, Ali NA, Kim J, Sehovic M, Zuckerman KS, Sallman DA, List AF, Padron E, Komrokji RS, Djulbegovic B, Extermann M, Sweet K, Lancet JE. Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality Blood. 130: 3912-3912. DOI: 10.1182/Blood.V130.Suppl_1.3912.3912 |
0.355 |
|
| 2017 |
Talati C, Kuykendall A, Ali NA, Kim J, Sehovic M, Zuckerman KS, Sallman DA, Padron E, List AF, Komrokji RS, Djulbegovic B, Extermann M, Sweet KL, Lancet JE. Hypomethylating Agents Versus Intensive Chemotherapy in Elderly Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count Blood. 130: 3911-3911. DOI: 10.1182/Blood.V130.Suppl_1.3911.3911 |
0.4 |
|
| 2017 |
Padron E, DeZern AE, Niyongere S, Ball MC, Balasis M, Ramadan H, Lancet JE, List AF, Mesa RA, Roboz GJ, Steensma DP, Sekeres MA, Komrokji RS. Promising Results of a Phase 1/2 Clinical Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia Blood. 130: 162-162. DOI: 10.1182/Blood.V130.Suppl_1.162.162 |
0.401 |
|
| 2017 |
Talati C, Kuykendall A, Al-Ali N, Komrokji R, Padron E, Sallman D, List A, Sweet K, Extermann M, Lancet J. Improved Responses with Azacitidine Compared to Decitabine in Patients with Acute Myeloid Leukemia in Patients ≥70 with Poor-Risk Cytogenetics Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.07.085 |
0.404 |
|
| 2016 |
Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone Marrow Cellularity at Day 14 Is the Most Important Predictive Factor for Response in Patients With AML Who Require Double-Induction Chemotherapy: Analysis From a Large, Single Institution Experience. American Journal of Hematology. PMID 28006850 DOI: 10.1002/Ajh.24627 |
0.386 |
|
| 2016 |
Zhang L, McGraw KL, Sallman DA, List AF. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leukemia & Lymphoma. 1-14. PMID 27967292 DOI: 10.1080/10428194.2016.1266625 |
0.685 |
|
| 2016 |
Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. The Lancet. Oncology. PMID 27927582 DOI: 10.1016/S1470-2045(16)30627-1 |
0.341 |
|
| 2016 |
Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V. Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS). Leukemia Research. 52: 50-57. PMID 27883945 DOI: 10.1016/J.Leukres.2016.11.008 |
0.445 |
|
| 2016 |
Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, ... ... List AF, et al. The NLRP3 Inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. PMID 27737891 DOI: 10.1182/Blood-2016-07-730556 |
0.64 |
|
| 2016 |
Ball M, List AF, Padron E. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. Blood. PMID 27707735 DOI: 10.1182/Blood-2016-07-692988 |
0.317 |
|
| 2016 |
Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, et al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 30: 2405-2409. PMID 27560106 DOI: 10.1038/Leu.2016.228 |
0.654 |
|
| 2016 |
Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale. Clinical Lymphoma, Myeloma & Leukemia. 16: S64-S66. PMID 27521328 DOI: 10.1016/J.Clml.2016.02.009 |
0.362 |
|
| 2016 |
Grabska J, Shah B, Reed D, Al Ali N, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience. Clinical Lymphoma, Myeloma & Leukemia. 16: S53-S56. PMID 27521325 DOI: 10.1016/J.Clml.2016.02.022 |
0.304 |
|
| 2016 |
Haider M, Al Ali N, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma & Leukemia. 16: S44-8. PMID 27521323 DOI: 10.1016/J.Clml.2016.02.017 |
0.344 |
|
| 2016 |
Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, et al. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. PMID 27418649 DOI: 10.3324/Haematol.2016.148999 |
0.368 |
|
| 2016 |
Sallman DA, Cluzeau T, Basiorka AA, List A. Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype. Frontiers in Oncology. 6: 151-151. PMID 27379212 DOI: 10.3389/Fonc.2016.00151 |
0.394 |
|
| 2016 |
Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF. Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. Cancer Research. PMID 27197154 DOI: 10.1158/0008-5472.Can-15-1756 |
0.641 |
|
| 2016 |
Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, et al. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Medicine. PMID 27098006 DOI: 10.1002/Cam4.721 |
0.393 |
|
| 2016 |
McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. PMID 27081179 DOI: 10.3324/Haematol.2016.143214 |
0.67 |
|
| 2016 |
Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Al Ali N, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, et al. The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes at the Time of Hypomethylating Agent Failure. Haematologica. PMID 26992944 DOI: 10.1182/Blood.V124.21.3275.3275 |
0.356 |
|
| 2016 |
Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. PMID 26944474 DOI: 10.3324/Haematol.2015.140335 |
0.315 |
|
| 2016 |
Zhang X, Sokol L, Bennett JM, Moscinski LC, List A, Zhang L. T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance. Leukemia Research. 43: 18-23. PMID 26927701 DOI: 10.1016/J.Leukres.2016.02.006 |
0.371 |
|
| 2016 |
Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Autoimmune Diseases and Myelodysplastic Syndromes. American Journal of Hematology. PMID 26875020 DOI: 10.1002/Ajh.24333 |
0.39 |
|
| 2016 |
Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, et al. A Multi-Institution Phase 1 Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26858309 DOI: 10.1158/1078-0432.Ccr-15-2781 |
0.376 |
|
| 2016 |
Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS, et al. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leukemia Research. 41: 43-7. PMID 26777537 DOI: 10.1016/J.Leukres.2015.12.007 |
0.41 |
|
| 2016 |
Platzbecker U, Komrokji RS, Fenaux P, Garcia-Manero G, Mufti GJ, Sekeres MA, Zhang J, Benzohra A, Laadem A, Vo B, Attie KM, List AF. A phase 3, randomized, double-blind study of luspatercept (ACE-536) in patients (pts) with Revised International Prognostic Scoring System (IPSS-R) very low- to intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts (RS) who require red blood cell (RBC) transfusions: The MEDALIST trial. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps7076 |
0.346 |
|
| 2016 |
Vela CM, Ho VQ, Frimpong JO, Brinda B, George T, Sweet KL, Padron E, Sallman D, List AF, Lancet JE, Komrokji RS. Treatment-Related Morbidity and Mortality Associated with Remission Induction in Adolescent and Young Adult (AYA) Versus Young Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Blood. 128: 5167-5167. DOI: 10.1182/Blood.V128.22.5167.5167 |
0.377 |
|
| 2016 |
Nazha A, Komrokji RS, Barnard J, Ali NHA, Roboz GJ, Steensma DP, DeZern AE, Fensterl J, Garcia-Manero G, List AF, Maciejewski JP, Sekeres MA. Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Blood. 128: 4332-4332. DOI: 10.1182/Blood.V128.22.4332.4332 |
0.371 |
|
| 2016 |
Komrokji RS, Sekeres MA, Barnard J, Alali N, DeZern AE, Padron E, Sallman D, Lancet JE, Roboz GJ, Fensterl J, Garcia-Manero G, Steensma DP, List AF. Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium Blood. 128: 4322-4322. DOI: 10.1182/Blood.V128.22.4322.4322 |
0.363 |
|
| 2016 |
Onida F, Iacobelli S, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho TL, Nazha A, Rampal RK, Sanchez ME, Jabbour EJ, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, ... ... List AF, et al. A New Clinically-Based Subclassification Proposal in CMML with Significant Prognostic Implications to Overcome the MDS/MPN Categorizing Dilemma Blood. 128: 4320-4320. DOI: 10.1182/Blood.V128.22.4320.4320 |
0.338 |
|
| 2016 |
Mcgraw KL, Nguyen J, Alali N, Song J, Sallman D, Padron E, Lancet JE, Qin D, Epling-Burnette P, Moscinski LC, Komrokji RS, List AF, Zhang L. EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome Blood. 128: 4305-4305. DOI: 10.1182/Blood.V128.22.4305.4305 |
0.691 |
|
| 2016 |
Sweet KL, Komrokji RS, Padron E, Cubitt CL, Khavarian L, List AF, Sallman D, Sullivan D, Chavez JC, Shah BD, Lancet JE. A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia Blood. 128: 4040-4040. DOI: 10.1182/Blood.V128.22.4040.4040 |
0.371 |
|
| 2016 |
Lancet JE, Komrokji RS, Sweet KL, Duong VH, McGraw KL, Zhang L, Nardelli LA, Ma Z, Reich RR, Padron E, List AF. Phase 2 Trial of Smoothened (SMO) Inhibitor PF-04449913 (PF-04) in Refractory Myelodysplastic Syndromes (MDS) Blood. 128: 3174-3174. DOI: 10.1182/Blood.V128.22.3174.3174 |
0.709 |
|
| 2016 |
Zhang Q, Ball M, Yulong Z, Balasis ME, List AF, Burnette PK, Komrokji RS, Padron E. Intrapatient Functional Clonality Deconvoluted By Coupling Intracellular Flow Cytometry and Next Generation Sequencing in Human Leukemia Blood. 128: 3161-3161. DOI: 10.1182/Blood.V128.22.3161.3161 |
0.347 |
|
| 2016 |
Hendrix K, Alali N, Padron E, Sallman D, List AF, Lancet JE, Komrokji RS. Myelodysplastic/Myeloproliferative Neoplasms Unclassified (MDS/MPN-U) Overlap: Can We Alter the Natural History? Blood. 128: 3125-3125. DOI: 10.1182/Blood.V128.22.3125.3125 |
0.424 |
|
| 2016 |
Kuykendall A, Talati C, Ali NA, Padron E, Sallman D, Lancet JE, Sweet KL, List AF, Zuckerman KS, Komrokji RS. Comparing Eras: Assessing Treatment Trends before and after Ruxolitinib Approval Blood. 128: 3124-3124. DOI: 10.1182/Blood.V128.22.3124.3124 |
0.395 |
|
| 2016 |
Gillis NK, Ball M, Zhang Q, Zhao Y, Yoder S, Balasis ME, Mesa TE, Sallman D, Lancet JE, Komrokji RS, List AF, McLeod HL, Rollison DE, Padron E. Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly Blood. 128: 295-295. DOI: 10.1182/Blood.V128.22.295.295 |
0.358 |
|
| 2016 |
Pogosova-Agadjanyan EL, Moseley A, Wood BL, Appelbaum FR, Chauncey T, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Othus M, Radich JP, Willman CL, Meshinchi S, et al. Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report Blood. 128: 2890-2890. DOI: 10.1182/Blood.V128.22.2890.2890 |
0.371 |
|
| 2016 |
Talati C, Marsh A, Baggett K, Al-Ali N, Sweet KL, Sallman D, Komrokji RS, List AF, Padron E, Lancet JE. Epigenetic Profiling in High-Risk MDS and AML Patients Identifies Pre-Treatment Methylation Patterns That Indicate Response to Hypomethylating Agents: A Pilot Study Blood. 128: 2885-2885. DOI: 10.1182/Blood.V128.22.2885.2885 |
0.376 |
|
| 2016 |
Santini V, Fenaux P, Giagounidis A, Platzbecker U, List AF, Zhong J, Wu C, Mavrommatis K, Beach CL, Hoenekopp A, MacBeth KJ. Impact of Somatic Gene Mutations on Response to Lenalidomide (LEN) in IPSS Lower-Risk Myelodysplastic Syndromes (MDS) Patients (Pts) without Del(5q) and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents (ESAs) Blood. 128: 225-225. DOI: 10.1182/Blood.V128.22.225.225 |
0.39 |
|
| 2016 |
List AF, Sun Z, Verma A, Bennett JM, McGraw KL, Nardelli LA, Maciejewski JP, Altman JK, Cheema P, Claxton DF, Komrokji RS, Luger S, Mattison R, Wassenaar T, Artz A, et al. Combined Treatment with Lenalidomide (LEN) and Epoetin Alfa (EA) Is Superior to Lenalidomide Alone in Patients with Erythropoietin (Epo)-Refractory, Lower Risk (LR) Non-Deletion 5q [Del(5q)] Myelodysplastic Syndrome (MDS): Results of the E2905 Intergroup Study-an ECOG-ACRIN Cancer Research Group Study, Grant CA180820, and the National Cancer Institute of the National Institutes of Health Blood. 128: 223-223. DOI: 10.1182/Blood.V128.22.223.223 |
0.702 |
|
| 2016 |
Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji RS, Moscinski LC, Padron E. Monocyte Subset Analysis Accurately Distinguishes Chronic Myelomonocytic Leukemia (CMML) from Myelodysplastic Syndromes (MDS) and Is Associated with a Favorable MDS Prognosis Blood. 128: 2009-2009. DOI: 10.1182/Blood.V128.22.2009.2009 |
0.397 |
|
| 2016 |
Basiorka AA, Ma Z, Mcgraw KL, Sallman D, Irvine BA, Al Ali NH, Padron E, Pinilla-Ibarz J, Komrokji RS, Sokol L, Wei S, List AF. NLRP3 Inflammasome-Derived ASC Specks Are a Diagnostic Biomarker for Myelodysplastic Syndromes (MDS) Blood. 128: 2005-2005. DOI: 10.1182/Blood.V128.22.2005.2005 |
0.63 |
|
| 2016 |
Ramadan H, Melody M, Steele A, Ali NHA, Padron E, Sallman D, Sweet KL, Lancet JE, List AF, Komrokji RS. Racial Disparities in Patients with Myelodysplastic Syndrome (MDS): Clinical and Molecular Depiction Blood. 128: 1997-1997. DOI: 10.1182/Blood.V128.22.1997.1997 |
0.446 |
|
| 2016 |
Zhang X, List AF, Lancet JE, Jinming S, Moscinski LC, Sokol L, Zhang L. Clinicopathological Features and Mutational Analysis of Patients with Aplastic Anemia and Hypoplastic Myelodysplastic Syndrome Blood. 128: 1993-1993. DOI: 10.1182/Blood.V128.22.1993.1993 |
0.357 |
|
| 2016 |
Melody M, Ali NHA, Zhang L, Ramadan H, Padron E, Sallman D, Sweet KL, Lancet JE, List AF, Bennett JM, Komrokji RS. Decoding Bone Marrow Fibrosis in Myelodysplastic Syndrome Blood. 128: 1985-1985. DOI: 10.1182/Blood.V128.22.1985.1985 |
0.445 |
|
| 2016 |
Sallman D, Padron E, Song J, Hussaini MO, Vaupel C, Ali NHA, Lancet JE, Hall J, List AF, Komrokji RS. Clinical Utility of Molecular Profiling in Higher Risk MDS Treated with Azacitidine: Can We Tailor Therapy Accordingly? Blood. 128: 1984-1984. DOI: 10.1182/Blood.V128.22.1984.1984 |
0.438 |
|
| 2016 |
Kuykendall A, Talati C, Ali NA, Padron E, Sallman D, Song J, Zhang L, Lancet JE, Sweet KL, List AF, Zuckerman KS, Komrokji RS. Validation of Genomic-Based Risk Models in Myelofibrosis and Proposal of Age-Independent Disease-Specific Models Blood. 128: 1947-1947. DOI: 10.1182/Blood.V128.22.1947.1947 |
0.382 |
|
| 2016 |
Kuykendall A, Talati C, Ali NHA, Padron E, Sallman D, Song J, Zhang L, Lancet JE, Sweet KL, List AF, Zuckerman KS, Komrokji RS. Mutation Landscape in Myelofibrosis: Assessment of Frequency and Correlation with Clinical Factors and Outcomes Blood. 128: 1946-1946. DOI: 10.1182/Blood.V128.22.1946.1946 |
0.377 |
|
| 2016 |
Kuykendall A, Talati C, Ali NHA, Padron E, Sallman D, Lancet JE, Sweet KL, List AF, Zuckerman KS, Komrokji RS. Characterization of Cytogenetic Abnormalities in Myelofibrosis and Relationship to Clinical Outcome Blood. 128: 1937-1937. DOI: 10.1182/Blood.V128.22.1937.1937 |
0.405 |
|
| 2016 |
Roe C, Alali N, Padron E, Burnette PK, Sweet KL, Sallman D, Sokol L, Lancet JE, List AF, Komrokji RS. Characterization of Myelodysplastic Syndromes (MDS) with T-Cell Large Granular Lymphocyte Proliferations (LGL) Blood. 128: 113-113. DOI: 10.1182/Blood.V128.22.113.113 |
0.461 |
|
| 2016 |
Kuendgen A, Tuechler H, Nomdedeu M, Haase D, Garcia-Manero G, Komrokji RS, Sole F, Sekeres MA, Porta MGD, List AF, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Loosdrecht AAvd, et al. Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) Blood. 128: 112-112. DOI: 10.1182/Blood.V128.22.112.112 |
0.37 |
|
| 2016 |
Niyongere S, Lucas N, Sansil S, Cubitt CL, Balasis ME, Kroeger J, Zhang Q, Ceremsak JJ, Stieglitz E, Zhao Y, Ball M, Komrokji RS, List AF, Santini V, Solary E, et al. Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML) Blood. 128: 109-109. DOI: 10.1182/Blood.V128.22.109.109 |
0.338 |
|
| 2016 |
McGraw K, Cheng C, Chen A, Genovese G, Cluzeau T, Lin H, Przychodzen B, Mallo M, Arenillas L, Mohamedali A, Ades L, Basiorka A, Irvine B, Sallman D, Padron E, ... ... List A, et al. Abstract 2570: Identification of genetic polymorphisms associated with myelodysplastic syndromes by genome-wide association study Cancer Research. 76: 2570-2570. DOI: 10.1158/1538-7445.Am2016-2570 |
0.655 |
|
| 2016 |
Ramadan H, Cameron A, Ali NA, Padron E, Sallman D, Lancet J, List A, Komrokji R. Racial Disparities in Patients with Myelodysplastic Syndrome (MDS): is There Really a Difference? Clinical Lymphoma, Myeloma & Leukemia. 16. DOI: 10.1016/J.Clml.2016.07.126 |
0.349 |
|
| 2016 |
Roe C, Ali N, Epling-Burnette PK, Bennett J, Padron E, Sallman D, Sokol L, Lancet J, List A, Komrokji R. T-Cell Large Granular Lymphocyte Proliferation (LGL) in Patients with Myelodysplastic Syndromes (MDS): Not an Innocent Bystander? Clinical Lymphoma, Myeloma & Leukemia. 16. DOI: 10.1016/J.Clml.2016.07.125 |
0.359 |
|
| 2016 |
Sweet K, Hussaini M, Lancet J, Komrokji R, List A, Moscinski L, Song J, Padron E. Impact of Persistent Somatic Mutations on Day 14 After Induction Chemotherapy for Acute Myeloid Leukemia Clinical Lymphoma, Myeloma & Leukemia. 16. DOI: 10.1016/J.Clml.2016.07.053 |
0.333 |
|
| 2015 |
Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw KL, Pellagatti A, ... ... List AF, et al. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America. 112: E6359-E6368. PMID 26578796 DOI: 10.1073/Pnas.1516394112 |
0.671 |
|
| 2015 |
Komrokji RS, List AF. Short- and Long-Term Benefits of Lenalidomide Treatment in Patients With Lower-Risk del(5q) Myelodysplastic Syndromes. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26504152 DOI: 10.1093/Annonc/Mdv488 |
0.44 |
|
| 2015 |
Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Al Ali N, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, ... List A, et al. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. PMID 26464171 DOI: 10.1038/Leu.2015.283 |
0.328 |
|
| 2015 |
Zeidan AM, Al Ali NH, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine. Clinical Lymphoma, Myeloma & Leukemia. PMID 26440749 DOI: 10.1016/J.Clml.2015.08.083 |
0.389 |
|
| 2015 |
McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget. PMID 26416416 DOI: 10.18632/Oncotarget.5255 |
0.655 |
|
| 2015 |
Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, ... ... List AF, et al. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms. Haematologica. 100: 1117-30. PMID 26341525 DOI: 10.3324/Haematol.2014.114660 |
0.306 |
|
| 2015 |
Komrokji R, Ramadan H, Al Ali N, Corrales-Yepez M, Zhang L, Padron E, Lancet J, List A. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma & Leukemia. 15: S60-3. PMID 26297280 DOI: 10.1016/J.Clml.2015.03.011 |
0.385 |
|
| 2015 |
Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? American Journal of Hematology. PMID 26284571 DOI: 10.1002/Ajh.24173 |
0.379 |
|
| 2015 |
Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better? American Journal of Hematology. PMID 26260295 DOI: 10.1002/Ajh.24170 |
0.324 |
|
| 2015 |
Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Colla S, Fenaux P, Kantarjian HM, Killick S, ... ... List AF, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer Journal. 5: e333. PMID 26230957 DOI: 10.1038/Bcj.2015.53 |
0.345 |
|
| 2015 |
Griffin PT, Komrokji RS, De Castro CM, Rizzieri DA, Melchert M, List AF, Lancet JE. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. American Journal of Hematology. 90: 796-9. PMID 26089240 DOI: 10.1002/Ajh.24087 |
0.394 |
|
| 2015 |
Pellagatti A, Roy S, Di Genua C, Burns A, McGraw K, Valletta S, Larrayoz MJ, Fernandez-Mercado M, Mason J, Killick S, Mecucci C, Calasanz MJ, List A, Schuh A, Boultwood J. Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression. Leukemia. PMID 25991409 DOI: 10.1038/Leu.2015.129 |
0.651 |
|
| 2015 |
Mishra A, Rollison DE, Brandon TH, Al Ali NH, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. Impact of tobacco usage on disease outcome in myelodysplastic syndromes. Leukemia Research. 39: 673-8. PMID 25934048 DOI: 10.1016/J.Leukres.2015.03.020 |
0.334 |
|
| 2015 |
McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, ... ... List AF, et al. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer Journal. 5: e291. PMID 25768405 DOI: 10.1038/bcj.2015.11 |
0.628 |
|
| 2015 |
Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, et al. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1157-64. PMID 25713434 DOI: 10.1200/Jco.2014.58.0571 |
0.402 |
|
| 2015 |
Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, ... ... List AF, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. 125: 1857-65. PMID 25624319 DOI: 10.1182/Blood-2014-10-607341 |
0.353 |
|
| 2015 |
Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannan Z, List A, Kantarjian H, Komrokji R. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 985-94. PMID 25480830 DOI: 10.1158/1078-0432.Ccr-14-1765 |
0.399 |
|
| 2015 |
Peker D, Padron E, Bennett JM, Zhang X, Horna P, Epling-Burnette PK, Lancet JE, Pinilla-Ibarz J, Moscinski L, List AF, Komrokji RS, Zhang L. A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution. Acta Haematologica. 133: 249-56. PMID 25413011 DOI: 10.1159/000365877 |
0.36 |
|
| 2015 |
Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, ... List AF, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 121: 876-82. PMID 25410759 DOI: 10.1002/Cncr.29145 |
0.36 |
|
| 2015 |
Sallman DA, Komrokji RS, Vaupel C, Ali NA, Lancet JE, List AF, Hall J, Padron E. Influence of variant allele frequency (VAF) on the phenotypic penetrance of TP53 mutations in myeloid malignancies. Journal of Clinical Oncology. 33: 7091-7091. DOI: 10.1200/Jco.2015.33.15_Suppl.7091 |
0.361 |
|
| 2015 |
Padron E, Dezern AE, Vaddi K, Scherle PA, Zhang Q, Ma Y, Balasis M, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, et al. A multi-institution phase I trial of ruxolitinib in chronic myelomonocytic leukemia (CMML). Journal of Clinical Oncology. 33: 7021-7021. DOI: 10.1200/Jco.2015.33.15_Suppl.7021 |
0.354 |
|
| 2015 |
Kuendgen A, Tuechler H, Nomdedeu M, Garcia-Manero G, Komrokji RS, Sekeres MA, Porta MGD, List AF, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Loosdrecht AAvd, Schlenk RF, Calvo X, et al. An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) Blood. 126: 609-609. DOI: 10.1182/Blood.V126.23.609.609 |
0.386 |
|
| 2015 |
Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Sallman D, Mishra A, Ali NHA, Nishihori T, Field T, Salem KZ, Perkins J, Zhang L, Moscinski LC, Fernandez HF, Lancet JE, List AF, et al. TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome Blood. 126: 4382-4382. DOI: 10.1182/Blood.V126.23.4382.4382 |
0.381 |
|
| 2015 |
Johnny N, McGraw KL, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L. P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Mutation Burden and Adverse Clinical Outcome in Myelodysplastic Syndromes Blood. 126: 4121-4121. DOI: 10.1182/Blood.V126.23.4121.4121 |
0.683 |
|
| 2015 |
Cluzeau T, McGraw KL, Irvine B, Masala E, Ades L, Basiorka AA, Mufti GJ, Maciejewski JP, Wei S, Fenaux P, Santini V, List AF. The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes Blood. 126: 355-355. DOI: 10.1182/Blood.V126.23.355.355 |
0.667 |
|
| 2015 |
Grabska J(, Shah BD, Ali NHA, Padron E, Ramadan H, Lancet JE, List AF, Komrokji RS. Myelodysplastic Syndromes in Adolescent Young Adults (AYA) Blood. 126: 2898-2898. DOI: 10.1182/Blood.V126.23.2898.2898 |
0.397 |
|
| 2015 |
Ramadan H, Duong VH, Ali NHA, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS. Eltrombopag Use in Chronic Myelomonocytic Leukemia (CMML) Patients: A Cautionary Tale Blood. 126: 2897-2897. DOI: 10.1182/Blood.V126.23.2897.2897 |
0.319 |
|
| 2015 |
Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Zell K, Zimmerman C, Ali NHA, Roboz GJ, Steensma DP, DeZern AE, Padron E, Jabbour EJ, Greenberg MD, List AF, Kantarjian HM, et al. A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure Blood. 126: 2888-2888. DOI: 10.1182/Blood.V126.23.2888.2888 |
0.368 |
|
| 2015 |
Sekeres MA, Swern AS, List AF, Fenaux P, Sugrue MM. Effect of Lenalidomide (LEN) Exposure on AML-Free Survival and Overall Survival in LEN-Treated Patients (Pts) with IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS) with Del(5q) Blood. 126: 2870-2870. DOI: 10.1182/Blood.V126.23.2870.2870 |
0.357 |
|
| 2015 |
Gerds AT, List AF, Giagounidis A, Hellström-Lindberg E, Li JS, Swern AS, Sugrue MM, Fenaux P, Sekeres MA. Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide Blood. 126: 2867-2867. DOI: 10.1182/Blood.V126.23.2867.2867 |
0.409 |
|
| 2015 |
Beatty MS, Hesterberg RS, Han Y, Padron E, Mailloux AW, Yoder S, Rajadhyaksha AM, List AF, Epling-Burnette PK. Cereblon Deficiency Leads to Alteration in c-Myc Regulated Genes, Increased Glucose Uptake and Resistance to JQ1 Bromodomain Inhibition Blood. 126: 286-286. DOI: 10.1182/Blood.V126.23.286.286 |
0.31 |
|
| 2015 |
Tinsley SM, Small BJ, Lancet JE, McMillan SC, Komrokji RS, Padron E, Zuckerman KS, List AF. What Is the Impact on Quality of Life of Various Treatments in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome? Rethinking the Goals Blood. 126: 2112-2112. DOI: 10.1182/Blood.V126.23.2112.2112 |
0.355 |
|
| 2015 |
Sallman D, Garcia-Manero G, Jabbour E, Sekeres MA, DeZern AE, Steensma DP, Roboz GJ, Barnard J, Ali NHA, Zimmerman C, Pierce S, Batista D, Lancet JE, Padron E, Maciejewski JP, ... List AF, et al. Impact of Hypomethylating Agent Therapy in Myelodysplastic Syndromes with Chromosome 3 Abnormalities Blood. 126: 1705-1705. DOI: 10.1182/Blood.V126.23.1705.1705 |
0.447 |
|
| 2015 |
Komrokji RS, DeZern AE, Zell K, Ali NHA, Padron E, Estling C, Zimmerman C, Hand W, Brown F, Rizzo N, Barnard J, Roboz GJ, Carraway HE, Maciejewski JP, List AF, et al. Response to Treatment Among SF3B1 Mutated Myelodysplastic Syndromes (MDS): A Case-Control Study from the MDS Clinical Research Consortium (MDS CRC) Blood. 126: 1697-1697. DOI: 10.1182/Blood.V126.23.1697.1697 |
0.384 |
|
| 2015 |
Sekeres MA, Zell K, Barnard J, DeZern AE, Steensma DP, Zimmerman C, Estling C, Hand W, Roboz GJ, Rizzo N, Ali NHA, List AF, Garcia-Manero G, Maciejewski JP, Komrokji RS. Long-Term Outcome of Myelodysplastic Syndromes (MDS) Patients Treated with Erythropoiesis Stimulating Agents (ESAs) Blood. 126: 1696-1696. DOI: 10.1182/Blood.V126.23.1696.1696 |
0.41 |
|
| 2015 |
Giagounidis A, List AF, Hellström-Lindberg E, Mufti GJ, Schlegelberger B, Morrill J, Wu C, Skikne BS, Fenaux P, Göhring G. Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies Blood. 126: 1680-1680. DOI: 10.1182/Blood.V126.23.1680.1680 |
0.384 |
|
| 2015 |
Sallman D, Padron E, Vaupel C, Cluzeau T, Ali NHA, Lancet JE, Hall J, List AF, Komrokji RS. Prognostic Impact of ASXL1 Mutations in MDS and CMML Blood. 126: 1673-1673. DOI: 10.1182/Blood.V126.23.1673.1673 |
0.384 |
|
| 2015 |
Valcarcel D, Verma A, Platzbecker U, Santini V, Giagounidis A, Díez-Campelo M, Janssen J, Schlenk RF, Gaidano G, Perez de Oteyza J, Cleverly AL, Chiang AY, Lahn M, Desiaih D, Guba SC, ... List AF, et al. Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes Blood. 126: 1669-1669. DOI: 10.1182/Blood.V126.23.1669.1669 |
0.404 |
|
| 2015 |
Komrokji RS, Haider M, Ali NHA, Lancet JE, Zhang Q, Epling-Burnette PK, List AF, Padron E. Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS) Blood. 126: 1664-1664. DOI: 10.1182/Blood.V126.23.1664.1664 |
0.365 |
|
| 2015 |
Mian SA, Kulasekararaj AG, Kizilors A, McGraw KL, Kordasti S, Menzel S, Smith Ae, Perezabellan P, Sallman D, List AF, Mufti GJ. NLRP3 Inflammosome Polymorphisms Are Enriched in Myelodysplastic Syndrome Patients with Autoimmune Disorders Blood. 126: 1659-1659. DOI: 10.1182/Blood.V126.23.1659.1659 |
0.683 |
|
| 2015 |
Ma Y, Rix LR, Zhang Q, Balasis ME, Komrokji RS, Rix U, List AF, Padron E. Pacritinib (PAC) Synergistically Potentiates Azacitidine (5AZA) Cytotoxicity in Chronic Myelomonocytic Leukemia (CMML) Blood. 126: 1658-1658. DOI: 10.1182/Blood.V126.23.1658.1658 |
0.349 |
|
| 2015 |
Balasis ME, Merelvede J, Kunigal S, Ren X, Ma Y, Zhang Q, Painter J, Droin NM, Johnson J, Yoder S, Komrokji RS, Zhang L, Wei S, Haferlach T, MacLeod R, ... List AF, et al. Molecular Characterization of SRSF2 Mutation Identifies a Clinically Relevant Lncrna (MALAT1) in Chronic Myelomonocytic Leukemia (CMML) Blood. 126: 1641-1641. DOI: 10.1182/Blood.V126.23.1641.1641 |
0.355 |
|
| 2015 |
Wei S, Eksioglu EA, Chen X, Cluzeau T, Basiorka A, Burnette A, Wei M, McGraw KL, Padron E, List AF. Inflammaging-Associated Metabolic Alterations Foster Development of the MDS Genotype Blood. 126: 144-144. DOI: 10.1182/Blood.V126.23.144.144 |
0.657 |
|
| 2015 |
Basiorka A, Mcgraw K, Eksioglu E, Chen X, Johnson J, Padron E, Komrokji R, Sokol L, Coll R, O'Neill L, Cooper M, Robertson A, Wei S, List A. 32 ACTIVATION OF REDOX-SENSITIVE INFLAMMASOMES UNDERLIES THE BIOLOGICAL PHENOTYPE OF MYELODYSPLASTIC SYNDROMES Leukemia Research. 39: S14. DOI: 10.1016/S0145-2126(15)30033-3 |
0.639 |
|
| 2015 |
Tinsley SM, Komrokji R, List AF. Predictors of Quality of Life for High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.164 |
0.304 |
|
| 2015 |
Haider M, Padron E, Epling-Burnette P, Lancet J, List A, Komrokji R. Immunosuppressive Therapy: Exploring An Underutilized Treatment Option For MDS Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.100 |
0.381 |
|
| 2015 |
Ramadan H, Duong V, Ali NA, Zhang L, Padron E, Lancet J, List A, Komrokji R. Eltrombopag use in Chronic Myleomonocytic Leukemia (CMML) Patients: A Cautionary Tale Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.099 |
0.311 |
|
| 2015 |
Grabska J, Shah B, Ali NA, Padron E, Ramadan H, Lancet J, List A, Komrokji R. Myelodysplastic Syndromes in Adolescent Young Adults – The Moffitt Experience Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.07.097 |
0.311 |
|
| 2015 |
Sallman D, Komrokji R, Vaupel C, Cluzeau T, McGraw KL, Al Ali NH, Lancet J, McGinniss MJ, Nahas S, Smith AE, Kulasekararaj A, Mufti G, List A, Hall J, Padron E. Impact of Mutation Variant Allele Frequency on Phenotype, Outcomes, and Patient Management in Myelodysplastic Syndromes Clinical Lymphoma Myeloma and Leukemia. 15: S43-S44. DOI: 10.1016/J.Clml.2015.07.092 |
0.639 |
|
| 2015 |
Cluzeau T, McGraw KL, Basiorka AA, Irvine BA, Zhang L, Burnette PE, Rollison DE, Mallo M, Sokol L, Sole F, Karsan A, Maciejewski J, List AF. TP53 and MDM2 single nucleotide polymorphisms influence survival in myelodysplastic syndromes Clinical Lymphoma Myeloma and Leukemia. 15: S42. DOI: 10.1016/J.Clml.2015.07.089 |
0.618 |
|
| 2015 |
Sallman D, Ali NA, Padron E, Lancet J, List A, Komrokji R. Chromosomal 3 Abnormalities in Myelodysplastic Syndromes: Implications on Prognosis and Response to Treatment Clinical Lymphoma, Myeloma & Leukemia. 15. DOI: 10.1016/J.Clml.2015.04.118 |
0.425 |
|
| 2014 |
McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors. Plos One. 9: e114249. PMID 25469886 DOI: 10.1182/Blood.V124.21.4623.4623 |
0.645 |
|
| 2014 |
Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstöcker M, Vyas P, List AF. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leukemia Research. 38: 1381-91. PMID 25444075 DOI: 10.1016/J.Leukres.2014.09.008 |
0.371 |
|
| 2014 |
Sallman DA, Wei S, List A. PP2A: The Achilles Heal in MDS with 5q Deletion. Frontiers in Oncology. 4: 264. PMID 25295231 DOI: 10.3389/Fonc.2014.00264 |
0.393 |
|
| 2014 |
Sekeres MA, Swern AS, Fenaux P, Greenberg PL, Sanz GF, Bennett JM, Dreyfus F, List AF, Li JS, Sugrue MM. Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). Blood Cancer Journal. 4: e242. PMID 25171203 DOI: 10.1038/Bcj.2014.62 |
0.373 |
|
| 2014 |
Duong VH, Komrokji RS, List AF. Update on the pharmacotherapy for myelodysplastic syndromes. Expert Opinion On Pharmacotherapy. 15: 1811-25. PMID 25080144 DOI: 10.1517/14656566.2014.937705 |
0.347 |
|
| 2014 |
Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. British Journal of Haematology. 167: 233-7. PMID 25039477 DOI: 10.1111/Bjh.13035 |
0.394 |
|
| 2014 |
Padron E, Yoder S, Kunigal S, Mesa T, Teer JK, Al Ali N, Sekeres MA, Painter JS, Zhang L, Lancet J, Maciejewski JP, Epling-Burnette PK, Sotomayor E, Komrokji RS, List AF. ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood. 123: 3675-7. PMID 24904105 DOI: 10.1182/Blood-2014-03-562637 |
0.345 |
|
| 2014 |
Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, et al. Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS. Blood. 124: 780-90. PMID 24891322 DOI: 10.1182/Blood-2014-01-552463 |
0.365 |
|
| 2014 |
Komrokji RS, Padron E, Yu D, Fulp WJ, Rodriguez Y, Tinsley S, List AF, Lancet JE. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes. American Journal of Hematology. 89: 809-12. PMID 24764152 DOI: 10.1182/Blood.V118.21.1714.1714 |
0.455 |
|
| 2014 |
Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber JM, Dennison B, Sekeres MA. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 120: 1670-6. PMID 24577838 DOI: 10.1002/Cncr.28631 |
0.353 |
|
| 2014 |
Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T. Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 776-80. PMID 24534108 DOI: 10.1016/J.Bbmt.2014.02.008 |
0.394 |
|
| 2014 |
Komrokji RS, Mailloux AW, Chen DT, Sekeres MA, Paquette R, Fulp WJ, Sugimori C, Paleveda-Pena J, Maciejewski JP, List AF, Epling-Burnette PK. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 99: 1176-83. PMID 24488560 DOI: 10.3324/Haematol.2012.083345 |
0.424 |
|
| 2014 |
Seymour JF, Bennett JM, List AF, Mufti GJ, Gore SD, Fenaux P, Santini V, Hetzer J, Songer S, Skikne BS, Beach CL. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. British Journal of Haematology. 165: 49-56. PMID 24467613 DOI: 10.1111/Bjh.12723 |
0.378 |
|
| 2014 |
Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS. Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure. Leukemia Research. 38: 443-6. PMID 24439565 DOI: 10.1016/J.Leukres.2013.12.010 |
0.38 |
|
| 2014 |
Fenaux P, Seymour JF, Santini V, Silverman L, Gore S, List A, Sanz G, Mufti GJ, Estey E, Swern AS, Beach CL, Hellstrom-Lindberg E. Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. Leukemia Research. 38: 258-62. PMID 24360612 DOI: 10.1016/J.Leukres.2013.10.014 |
0.35 |
|
| 2014 |
List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS. Leukemia. 28: 1033-40. PMID 24150217 DOI: 10.1038/Leu.2013.305 |
0.458 |
|
| 2014 |
Giagounidis A, Mufti GJ, Fenaux P, Germing U, List A, MacBeth KJ. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes. Annals of Hematology. 93: 1-11. PMID 24018623 DOI: 10.1007/S00277-013-1863-5 |
0.415 |
|
| 2014 |
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Velasco Mr, Gaur R, Atallah E, Attar E, Appelbaum FR, Erba HP. A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117 Blood. 124: LBA-5-LBA-5. DOI: 10.1182/Blood.V124.21.Lba-5.Lba-5 |
0.406 |
|
| 2014 |
Shao H, Nishihori T, Shain KH, Baz R, Alsina M, Padron E, Lancet JE, List AF, Komrokji RS, Zhang L. Concurrent De Novo Myeloid Neoplasm and Plasma Cell Dyscrasia: A Clinicopathologic Study of 27 Cases Blood. 124: 5620-5620. DOI: 10.1182/Blood.V124.21.5620.5620 |
0.444 |
|
| 2014 |
Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, Rampal RK, Sanchez ME, Jabbour E, Al Ali NH, Thompson Z, Lee J, Colla S, Fenaux P, Kantarjian HM, ... ... List AF, et al. An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies Blood. 124: 530-530. DOI: 10.1182/Blood.V124.21.530.530 |
0.337 |
|
| 2014 |
Negoro E, Polprasert C, Radivoyevitch T, Adema V, Hosono N, Makishima H, Przychodzen B, Sekeres MA, Santini V, McGaw K, List AF, Sole F, Maciejewski JP. Molecular Predictors of Response in Patients with Myeloid Neoplasms Treated with Lenalidomide Blood. 126: 2853-2853. DOI: 10.1182/Blood.V124.21.4665.4665 |
0.436 |
|
| 2014 |
Komrokji RS, Padron E, Ali NHA, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF. Prognostic Value of Circulating Myeloblasts in Patients with Myelodysplastic Syndromes (MDS): A Proposal for Incorporation in the Revised International Prognostic Scoring System (R-IPSS) Blood. 124: 4650-4650. DOI: 10.1182/Blood.V124.21.4650.4650 |
0.369 |
|
| 2014 |
Sallman D, Ali NHA, Padron E, Lancet JE, List AF, Komrokji RS. Chromosomal 3 Abnormalities in Myelodysplastic Syndromes: Implications on Prognosis and Response to Treatment Blood. 124: 4632-4632. DOI: 10.1182/Blood.V124.21.4632.4632 |
0.443 |
|
| 2014 |
Eksioglu EA, Heider K, Rueter B, Burnette A, Wei M, McGraw K, Basiorka AA, Patel P, Lancet J, Komrokji R, List AF, Wei S. Novel Therapeutic Approach to Improve Hematopoiesis By Targeting Myeloid Derived Suppressor Cells with a Humanized Anti-CD33 Antibody Blood. 124: 4597-4597. DOI: 10.1182/Blood.V124.21.4597.4597 |
0.646 |
|
| 2014 |
Rollison DE, Shain KH, Lee J, Hampras SS, Fisher K, Al Ali NH, Padron E, Lancet JE, Olesnyckyj M, Kenvin L, Knight RD, Dalton W, List AF, Komrokji R. Subsequent Primary Malignancies Among Myelodysplastic Syndrome Patients Treated with or without Lenalidomide Blood. 124: 413-413. DOI: 10.1182/Blood.V124.21.413.413 |
0.425 |
|
| 2014 |
Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Ali NHA, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour E, Greenberg MD, Lee S, List AF, Kantarjian HM, Maciejewski JP, et al. Outcomes of Patients with Myelodysplastic Syndromes (MDS) Who Achieve Stable Disease after Treatment with Hypomethylating Agents (HMA) Blood. 124: 3273-3273. DOI: 10.1182/Blood.V124.21.3273.3273 |
0.363 |
|
| 2014 |
Giagounidis A, List AF, Hellstrom-Lindberg E, Mufti GJ, Schlegelberger B, Morrill J, Wu C, Skikne B, Fenaux P, Göhring G. Prevalence and Clinical Impact of Additional Cytogenetic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Deletion 5q from the MDS-003 and MDS-004 Studies Blood. 124: 3270-3270. DOI: 10.1182/Blood.V124.21.3270.3270 |
0.375 |
|
| 2014 |
Komrokji RS, Garcia-Manero G, Ades L, Laadem A, Vo B, Prebet T, Stamatoullas A, Boyd T, Delaunay J, Steensma DP, Sekeres MA, Beyne-Rauzy O, Zou J, Attie K, Sherman ML, ... ... List AF, et al. An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion Blood. 124: 3251-3251. DOI: 10.1182/Blood.V124.21.3251.3251 |
0.324 |
|
| 2014 |
Zeidan AM, Sekeres MA, Garcia-Manero G, Barnard J, Ali NHA, Zimmerman C, Roboz GJ, Steensma DP, DeZern AE, Jabbour E, Kantarjian H, Zell K, Wang Q, Gore SD, Nazha A, ... ... List AF, et al. The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA) Blood. 124: 1935-1935. DOI: 10.1182/Blood.V124.21.1935.1935 |
0.377 |
|
| 2014 |
Rollison DE, Shain KH, Lee J, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Knight RD, List AF, Dalton W, Komrokji R. Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients Blood. 124: 1912-1912. DOI: 10.1182/Blood.V124.21.1912.1912 |
0.42 |
|
| 2014 |
Pellagatti A, Di Genua C, Roy S, Burns A, McGraw KL, Larrayoz MJ, Fernandez-Mercado M, Valletta S, Mason J, Killick S, Mecucci C, Calasanz MJ, List AF, Schuh A, Boultwood J. Targeted Re-Sequencing Analysis of 31 Genes Commonly Mutated in Myeloid Disorders in Serial Samples from Myelodysplastic Syndrome Patients with Disease Progression Blood. 124: 1901-1901. DOI: 10.1182/Blood.V124.21.1901.1901 |
0.646 |
|
| 2014 |
Abel GA, Efficace F, Buckstein R, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, List AF, Klaassen RJ. Preliminary International Validation of the Quality of Life in Myelodysplasia Scale (QUALMS) Blood. 124: 1328-1328. DOI: 10.1182/Blood.V124.21.1328.1328 |
0.329 |
|
| 2014 |
Field T, Perkins J, Hillgruber R, Nishihori T, Tomblyn MR, Mishra A, Pidala J, Locke F, Perez LE, Betts B, Ayala E, Alsina M, Ochoa J, Padron E, Lancet J, ... ... List AF, et al. Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients up to Age Seventy-Five with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.374 |
0.325 |
|
| 2013 |
Komrokji RS, Padron E, Ebert BL, List AF. Deletion 5q MDS: molecular and therapeutic implications. Best Practice & Research. Clinical Haematology. 26: 365-75. PMID 24507813 DOI: 10.1016/J.Beha.2013.10.013 |
0.365 |
|
| 2013 |
Komrokji RS, Padron E, Lancet JE, List AF. Prognostic factors and risk models in myelodysplastic syndromes. Clinical Lymphoma, Myeloma & Leukemia. 13: S295-9. PMID 24290214 DOI: 10.1016/J.Clml.2013.05.022 |
0.332 |
|
| 2013 |
Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, Epling-Burnette P, Van Bijnen S, Dolstra H, Cannon J, Youn JI, Donatelli SS, Qin D, De Witte T, Tao J, ... ... List A, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. The Journal of Clinical Investigation. 123: 4595-611. PMID 24216507 DOI: 10.1172/Jci67580 |
0.354 |
|
| 2013 |
Duong VH, Padron E, List AF, Komrokji RS. Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice? Expert Review of Hematology. 6: 485-7. PMID 24083503 DOI: 10.1586/17474086.2013.827884 |
0.433 |
|
| 2013 |
Duong VH, Lin K, Reljic T, Kumar A, Al Ali NH, Lancet JE, List AF, Komrokji RS. Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure. Clinical Lymphoma, Myeloma & Leukemia. 13: 711-5. PMID 24054159 DOI: 10.1016/J.Clml.2013.07.007 |
0.4 |
|
| 2013 |
Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, ... ... List AF, et al. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proceedings of the National Academy of Sciences of the United States of America. 110: 16127-32. PMID 24043769 DOI: 10.1073/Pnas.1311055110 |
0.68 |
|
| 2013 |
Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leukemia Research. 37: 1461-7. PMID 23993427 DOI: 10.1016/J.Leukres.2013.07.034 |
0.347 |
|
| 2013 |
Pogosova-Agadjanyan EL, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, May JJ, Oehler VG, Petersdorf S, Pogosov GL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL. The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. Plos One. 8: e70812. PMID 23967110 DOI: 10.1371/Journal.Pone.0070812 |
0.367 |
|
| 2013 |
Jerez A, Clemente MJ, Makishima H, Rajala H, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj A, Afable M, Husseinzadeh HD, Hosono N, LeBlanc F, Lagström S, Zhang D, ... ... List AF, et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood. 122: 2453-9. PMID 23926297 DOI: 10.1182/Blood-2013-04-494930 |
0.685 |
|
| 2013 |
Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf SH, Godwin JE, Willman CL, Pierce SA, List AF, et al. A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia. British Journal of Haematology. 163: 130-2. PMID 23829510 DOI: 10.1111/Bjh.12450 |
0.332 |
|
| 2013 |
Komrokji RS, Raza A, Lancet JE, Ren C, Taft D, Maniar M, Wilhelm F, List AF. Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. British Journal of Haematology. 162: 517-24. PMID 23789936 DOI: 10.1111/Bjh.12436 |
0.362 |
|
| 2013 |
Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 121: 5068-77. PMID 23632888 DOI: 10.1182/Blood-2012-10-460170 |
0.653 |
|
| 2013 |
Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. American Journal of Hematology. 88: 566-70. PMID 23605934 DOI: 10.1002/Ajh.23454 |
0.398 |
|
| 2013 |
Trimaldi J, Carballido EM, Bowers JW, Anguiano AL, Zhang ZJ, Shah BD, Bruno S, List AF, Moscinski LC, Grady T, Agosti SJ, Kang L, Zhang L. B-lymphoblastic leukemia/lymphoma associated with t(8;13)(p11;q12)/ ZMYM2 (ZNF198)-FGFR1 : rare case and review of the literature. Acta Haematologica. 130: 127-34. PMID 23594707 DOI: 10.1159/000347030 |
0.352 |
|
| 2013 |
Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF, Hellström-Lindberg E, Swern AS, Beach CL, List AF. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 98: 1067-72. PMID 23585522 DOI: 10.3324/Haematol.2012.074831 |
0.357 |
|
| 2013 |
Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia. 27: 1301-9. PMID 23486531 DOI: 10.1038/Leu.2013.80 |
0.314 |
|
| 2013 |
Adès L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, Maciejewski JP, Dreyfus F, List AF, Fenaux P, Komrokji RS. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leukemia Research. 37: 609-13. PMID 23415110 DOI: 10.1016/J.Leukres.2013.01.004 |
0.406 |
|
| 2013 |
Duong VH, Lancet JE, Alrawi E, Al-Ali NH, Perkins J, Field T, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leukemia Research. 37: 510-5. PMID 23332452 DOI: 10.1016/J.Leukres.2012.12.012 |
0.407 |
|
| 2013 |
Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy. Leukemia Research. 37: 300-4. PMID 23273539 DOI: 10.1016/J.Leukres.2012.11.001 |
0.399 |
|
| 2013 |
Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis AA, Brandenburg NA, Backstrom J, Glasmacher A, Hasford J, Germing U. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia. 27: 1072-9. PMID 23257782 DOI: 10.1038/Leu.2012.369 |
0.436 |
|
| 2013 |
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. British Journal of Haematology. 160: 177-87. PMID 23157224 DOI: 10.1111/Bjh.12103 |
0.629 |
|
| 2013 |
Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK. Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 27: 897-906. PMID 23072779 DOI: 10.1038/Leu.2012.300 |
0.645 |
|
| 2013 |
Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, ... List AF, et al. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 27: 977-80. PMID 23032694 DOI: 10.1038/Leu.2012.264 |
0.341 |
|
| 2013 |
Kar SA, Jankowska A, Makishima H, Visconte V, Jerez A, Sugimoto Y, Muramatsu H, Traina F, Afable M, Guinta K, Tiu RV, Przychodzen B, Sakaguchi H, Kojima S, Sekeres MA, ... List AF, et al. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia. Haematologica. 98: 107-13. PMID 22773603 DOI: 10.3324/Haematol.2012.064048 |
0.354 |
|
| 2013 |
Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, ... ... List A, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene. 32: 1110-20. PMID 22525275 DOI: 10.1038/Onc.2012.139 |
0.666 |
|
| 2013 |
Wang H, Chen X, Eksioglu EA, Zhou J, Fortenbery NR, Djeu J, List A, Wei S. Lenalidomide and Arsenic Trioxide Have Independent Non-Interfering Effects When Used in Combination on Myeloma Cell Lines in Vitro Journal of Cancer Therapy. 4: 787-796. DOI: 10.4236/Jct.2013.43095 |
0.329 |
|
| 2013 |
Prithviraj GK, Mathew BM, Komrokji RK, List AF, Padron E. Chronic myelomonocytic leukemia: a review of the molecular biology, prognostic models and treatment International Journal of Hematologic Oncology. 2: 151-162. DOI: 10.2217/Ijh.13.12 |
0.346 |
|
| 2013 |
McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. Recruitment of Epo-R into lipid rafts is dependent on Rac1 and RhoA GTPase activation. Plos One. DOI: 10.1371/Journal.Pone.0034477.G006 |
0.577 |
|
| 2013 |
Advani AS, McDonough S, Copelan E, Willman CL, Mulford DA, List AF, Sekeres MA, Othus M, Erba HP, Appelbaum FR. SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML). Journal of Clinical Oncology. 31: 7028-7028. DOI: 10.1200/Jco.2013.31.15_Suppl.7028 |
0.346 |
|
| 2013 |
Epling-Burnette PK, Han Y, Mailloux AW, Zhang L, McDaniel JM, Anjali R, Wei S, David R, Neeson P, Komrokji RS, List A. Novel Predictor Of Lenalidomide Response In Non-del5q MDS Reveals Linkage To Molecular Mechanism: First Characterization Of T-Cell Function In Cereblon Homozygous Deficient Mice Blood. 122: 748-748. DOI: 10.1182/Blood.V122.21.748.748 |
0.342 |
|
| 2013 |
Komrokji RS, Kulasekararaj AG, Ali NHA, Kordasti SY, Bart-smith E, Benjamin C, Padron E, Zhang L, Lancet JE, List A, Mufti GJ, Epling-Burnette PK. Characteristics and Outcome Of Myelodysplastic Syndromes (MDS) Patients With Autoimmune Diseases Blood. 122: 746-746. DOI: 10.1182/Blood.V122.21.746.746 |
0.408 |
|
| 2013 |
Makishima H, Przychodzen BP, Jerez A, Polprasert C, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Yoshida K, Sanada M, Boultwood J, List A, Sekeres MA, Ogawa S, Maciejewski JP. Whole Exome Sequencing (“mutatome”) Of Deletion 5q Blood. 122: 656-656. DOI: 10.1182/Blood.V122.21.656.656 |
0.374 |
|
| 2013 |
Field T, List A, Anasetti C, Perkins J, Ali NHA, Mishra A, Padron E, Lancet JE, Kharfan-Dabaja MA, Komrokji RS. Utility Of Revised International Prognostic Scoring System (R-IPSS) To Predict Outcome Of Myelodysplastic Syndromes (MDS) Patients After Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Blood. 122: 5222-5222. DOI: 10.1182/Blood.V122.21.5222.5222 |
0.359 |
|
| 2013 |
Moscinski LC, Komrokji RS, Padron E, Sagatys EM, Naghashpour M, Tao J, Bennett JM, List A, Lancet JE, Zuckerman KS, Zhang L. Clinical Features and Outcome Of Clonal Mastocytosis Secondary To Chronic Myelomonocytic Leukemia (SM- AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study Blood. 122: 4076-4076. DOI: 10.1182/Blood.V122.21.4076.4076 |
0.398 |
|
| 2013 |
Ho VQ, Cade R, Wetzstein GA, Hoang VD, List A, Padron E, Fernandez HF, Lancet JE, Komrokji RS. A Comparison Of Acute Myelogenous Leukemia Induction Therapies: High Dose Daunorubicin Vs Idarubicin Blood. 122: 3951-3951. DOI: 10.1182/Blood.V122.21.3951.3951 |
0.397 |
|
| 2013 |
Sekeres MA, Swern AS, Giagounidis A, List A, Schlegelberger B, Fenaux P, Li JS, Sugrue MM. Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and AML-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q) Blood. 122: 390-390. DOI: 10.1182/Blood.V122.21.390.390 |
0.404 |
|
| 2013 |
Sebert M, Komrokji RS, Sekeres MA, Prebet T, Cluzeau T, Santini V, Sanna A, Ali NHA, Hobson S, Eclache V, List A, Fenaux P, Ades L. Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients Blood. 122: 389-389. DOI: 10.1182/Blood.V122.21.389.389 |
0.416 |
|
| 2013 |
Sekeres MA, List AF, Khoury HJ, Advani A, Jabbour E, Kantarjian HM, Lancet JE, Cable L, Guthrie K, Hogeland G, Ptaszynski M, Maloney L, Corson D, Komrokji RS. Phase 1 Dose-Escalation/Expansion Study Of ARRY-614 In Patients With IPSS Low/Int-1 Risk Myelodysplastic Syndromes Blood. 122: 387-387. DOI: 10.1182/Blood.V122.21.387.387 |
0.344 |
|
| 2013 |
Kunigal S, Teer J, Painter J, Yoder SJ, Kim E, Zhang L, Lancet JE, Komrokji RS, Abdel-Wahab O, List A, Epling-Burnette PK, Padron E. JAK2 Dependent GM-CSF Signaling Triggers SRSF2 Phosphorylation: A Potential Cause Of Mutation-Independent RNA Splicing Aberrancy In CMML Blood. 122: 2772-2772. DOI: 10.1182/Blood.V122.21.2772.2772 |
0.327 |
|
| 2013 |
Ali NHA, Kharfan-Dabaja MA, Padron E, Zhang L, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza) Blood. 122: 2771-2771. DOI: 10.1182/Blood.V122.21.2771.2771 |
0.31 |
|
| 2013 |
Duong VH, Zhang L, Lee J, Padron E, Lancet JE, List A. A Sequential Two-Stage Dose Escalation Study Evaluating The Safety and Efficacy Of Eltrombopag In Thrombocytopenic Patients With Myelodysplastic Syndrome (MDS) Resistant To Hypomethylating Agents (HMA) Blood. 122: 2760-2760. DOI: 10.1182/Blood.V122.21.2760.2760 |
0.352 |
|
| 2013 |
Field T, Perkins J, Tomblyn M, Hillgruber R, Nishihori T, Mishra A, Pidala J, Ayala E, Locke FL, Alsina M, Betts BC, Padron E, Fernandez HF, Lancet JE, List A, et al. Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine Blood. 122: 2152-2152. DOI: 10.1182/Blood.V122.21.2152.2152 |
0.358 |
|
| 2013 |
Keerthivasan G, Zhao B, Harris CE, Zhang L, Gao J, McElherne J, Yang J, Basiorka AA, Schipma M, Boultwood J, Verma A, List A, Williams DA, Ji P. Aberrant Overexpression Of CD14 In Granulocytes Sensitizes Innate Immune Response In mDia1 Heterozygous Myelodysplastic Syndromes Blood. 122: 1557-1557. DOI: 10.1182/Blood.V122.21.1557.1557 |
0.378 |
|
| 2013 |
List A, Hellström-Lindberg E, Sekeres MA, Mufti GJ, Schlegelberger B, Morrill J, Wu C, Skikne BS, Fenaux P, Göhring G. Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004 Blood. 122: 1538-1538. DOI: 10.1182/Blood.V122.21.1538.1538 |
0.439 |
|
| 2013 |
Corrales-Yepez MG, Ali NHA, Padron E, Lancet JE, List A. Lenalidomide Treatment For Lower Risk Non-Deletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Prior To Azanucleosides Blood. 122: 1507-1507. DOI: 10.1182/Blood.V122.21.1507.1507 |
0.376 |
|
| 2013 |
Komrokji RS, Ali NHA, Padron E, Lee J, Hillgruber N, Tinsley S, Lancet JE, List A. A Phase II Clinical Trial Of Lenalidomide and Prednisone In Low and Intermediate-1 IPSS Risk, Non-Del (5q) MDS Patients Blood. 122: 1506-1506. DOI: 10.1182/Blood.V122.21.1506.1506 |
0.419 |
|
| 2013 |
Komrokji RS, Wang X, Ali NHA, Garcia-Manero G, Steensma DP, Roboz GJ, Gore SD, Hobson S, Zimmerman C, Padron E, Maciejewski JP, List A, Sekeres MA. Comparing The Prognostic Value Of Risk Stratifying Models For Patients With Lower-Risk Myelodysplastic Syndromes (MDS): Is One Model Better? A Report on The Behalf of The MDS Clinical Research Consortium Blood. 122: 1505-1505. DOI: 10.1182/Blood.V122.21.1505.1505 |
0.375 |
|
| 2013 |
Ostronoff F, Othus M, Meshinchi S, Godwin JE, Kopecky KJ, List A, Oehler VG, Petersdorf S, Pogosova-Agadjanyan EL, Radich J, Willman CL, Appelbaum FR, Stirewalt DL. Prognostic Significance Of NPM1 mutations In The Absence Of FLT3-ITD in Older Patients With AML: A SWOG Report Blood. 122: 1315-1315. DOI: 10.1182/Blood.V122.21.1315.1315 |
0.422 |
|
| 2013 |
Vigil CE, Tan W, Wilding G, Garcia-Manero G, Wang ES, Wetzler M, List AF. Comparison of Outcome in Erythroleukemia Patients Treated with Standard Chemotherapy Regimens or Hypomethylating Agents Clinical Lymphoma, Myeloma & Leukemia. 13. DOI: 10.1016/J.Clml.2013.07.090 |
0.324 |
|
| 2012 |
Duong VH, Komrokji RS, List AF. Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion. Therapeutic Advances in Hematology. 3: 105-16. PMID 23556117 DOI: 10.1177/2040620711435659 |
0.392 |
|
| 2012 |
Epling-Burnette PK, McDaniel J, Wei S, List AF. Emerging immunosuppressive drugs in myelodysplastic syndromes. Expert Opinion On Emerging Drugs. 17: 519-41. PMID 23163589 DOI: 10.1517/14728214.2012.736487 |
0.358 |
|
| 2012 |
Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. American Journal of Hematology. 87: 1006-9. PMID 23090887 DOI: 10.1002/Ajh.23303 |
0.412 |
|
| 2012 |
Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control : Journal of the Moffitt Cancer Center. 19: 4-15. PMID 23042420 DOI: 10.1177/107327481201904S04 |
0.385 |
|
| 2012 |
Komrokji RS, Lancet JE, Swern AS, Chen N, Paleveda J, Lush R, Saba HI, List AF. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood. 120: 3419-24. PMID 22936658 DOI: 10.1182/Blood-2012-03-415661 |
0.378 |
|
| 2012 |
Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, ... List AF, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood. 120: 4945-51. PMID 22915641 DOI: 10.1182/Blood-2012-06-434639 |
0.4 |
|
| 2012 |
Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. Journal of Immunology (Baltimore, Md. : 1950). 189: 3198-208. PMID 22875800 DOI: 10.4049/Jimmunol.1200602 |
0.404 |
|
| 2012 |
Jerez A, Clemente MJ, Makishima H, Koskela H, Leblanc F, Peng Ng K, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, ... ... List A, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 120: 3048-57. PMID 22859607 DOI: 10.1182/Blood-2012-06-435297 |
0.651 |
|
| 2012 |
Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer Journal. 2: e63. PMID 22829258 DOI: 10.1038/Bcj.2012.7 |
0.399 |
|
| 2012 |
Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1. Cancer Research. 72: 4204-13. PMID 22761337 DOI: 10.1158/0008-5472.Can-12-0743 |
0.605 |
|
| 2012 |
Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, ... ... List AF, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 120: 2076-86. PMID 22753872 DOI: 10.1182/Blood-2011-12-399683 |
0.357 |
|
| 2012 |
Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes. Current Pharmaceutical Design. 18: 3198-203. PMID 22571699 DOI: 10.2174/1381612811209023198 |
0.401 |
|
| 2012 |
Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, ... ... List A, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood. 119: 6109-17. PMID 22553315 DOI: 10.1182/Blood-2011-12-397620 |
0.671 |
|
| 2012 |
List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2134-9. PMID 22547607 DOI: 10.1200/Jco.2010.34.1222 |
0.315 |
|
| 2012 |
McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. Erythropoietin receptor signaling is membrane raft dependent. Plos One. 7: e34477. PMID 22509308 DOI: 10.1371/Journal.Pone.0034477 |
0.606 |
|
| 2012 |
Sugimoto Y, Sekeres MA, Makishima H, Traina F, Visconte V, Jankowska A, Jerez A, Szpurka H, O'Keefe CL, Guinta K, Afable M, Tiu R, McGraw KL, List AF, Maciejewski J. Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide. Journal of Hematology & Oncology. 5: 4. PMID 22390313 DOI: 10.1186/1756-8722-5-4 |
0.665 |
|
| 2012 |
Nyland SB, Krissinger DJ, Clemente MJ, Irby RB, Baab KT, Jarbadan NR, Sokol L, Schaefer E, Liao J, Cuthbertson D, Epling-Burnette P, Paquette R, List AF, Maciejewski JP, Loughran TP. Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study. Leukemia Research. 36: 581-7. PMID 22386729 DOI: 10.1016/J.Leukres.2012.02.001 |
0.34 |
|
| 2012 |
Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 118: 2659-64. PMID 21956402 DOI: 10.1002/Cncr.26567 |
0.387 |
|
| 2012 |
Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer. 118: 2138-47. PMID 21887679 DOI: 10.1002/Cncr.26469 |
0.426 |
|
| 2012 |
Mathew RA, Bennett JM, Liu JJ, Komrokji RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC, Zhang L. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leukemia Research. 36: 72-80. PMID 21782240 DOI: 10.1016/J.Leukres.2011.05.003 |
0.384 |
|
| 2012 |
Mailloux AW, List AF, Epling-Burnette PK. Response to comment on "expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome" Journal of Immunology. 189: 4199-4200. DOI: 10.4049/Jimmunol.1290064 |
0.315 |
|
| 2012 |
Apuri S, Lancet JE, Ali NHA, Padron E, Ho VQ, Pinilla-Ibarz J, List AF, Komrokji RS. Evidence for Selective Benefit of Sequential Treatment with Azanucleosides in Patients with Myelodysplastic Syndromes (MDS) Blood. 120: 4937-4937. DOI: 10.1200/Jco.2013.31.15_Suppl.7113 |
0.38 |
|
| 2012 |
Khan AM, Lancet JE, Kharfan-Dabaja MA, Ali NA, List AF, Komrokji RS. Albumin as a prognostic factor for overall survival in newly diagnosed patients with acute myeloid leukemia (AML). Journal of Clinical Oncology. 30: 6586-6586. DOI: 10.1200/Jco.2012.30.15_Suppl.6586 |
0.378 |
|
| 2012 |
Fenaux P, Guerci-Bresler A, Muus P, Sekeres MA, Giagounidis A, Deeg HJ, Greenberg P, Skikne B, Yu X, List AF. Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q. Journal of Clinical Oncology. 30: 6522-6522. DOI: 10.1200/Jco.2012.30.15_Suppl.6522 |
0.338 |
|
| 2012 |
Raza A, Komrokji RS, Brooks R, Lancet JE, List AF, Ren C, Taft DR, Wilhelm F, Maniar M. A phase I study to assess oral bioavailability of a novel oral soft gelatin capsule formulation of rigosertib (ON 01910.Na) under fasted and fed conditions in patients with myelodysplastic syndromes. Journal of Clinical Oncology. 30: 3081-3081. DOI: 10.1200/Jco.2012.30.15_Suppl.3081 |
0.302 |
|
| 2012 |
Caceres G, Johnson J, McGraw KL, Basiorka AA, Liu K, Smith LJ, Daugherty FJ, Wei S, Komrokji RS, Zhang L, Littleton N, Wells RA, Sokol L, List AF. Targeted Repression of TP53 Promotes Erythropoiesis in Del(5q) MDS and Overcomes Clinical Resistance to Lenalidomide Blood. 120: 920-920. DOI: 10.1182/Blood.V120.21.920.920 |
0.669 |
|
| 2012 |
Jerez A, Clemente MJ, Makishima H, Koskela HLM, Gómez-Seguí I, Olson T, McGraw K, Przychodzen B, Kulasekararaj AG, Afable MG, Husseinzadeh HD, Evans EP, Hosono N, LeBlanc F, Lagström S, ... ... List AF, et al. STAT3-Mutations Indicate the Presence of Subclinical Self-Reactive Cytotoxic T Cell Clones in Aplastic Anemia and Myelodysplastic Syndromes Blood. 120: 646-646. DOI: 10.1182/Blood.V120.21.646.646 |
0.685 |
|
| 2012 |
Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber J, Dennison B, Sekeres MA. Disparity in Perceptions of Disease, Treatment Effectiveness and Treatment Adherence Between Physicians and Patients with Myelodysplastic Syndromes (MDS) Blood. 120: 4949-4949. DOI: 10.1182/Blood.V120.21.4949.4949 |
0.342 |
|
| 2012 |
Papenhausen P, Schwartz S, Dong HY, List AF, Thomason R. Utility of SNP Microarray in the Diagnosis of MDS Blood. 120: 4806-4806. DOI: 10.1182/Blood.V120.21.4806.4806 |
0.384 |
|
| 2012 |
Apuri S, Ali NHA, List AF, Padron E, Komrokji RS, Lancet JE. Outcomes in Patients with Acute Myeloid Leukemia Preceded by Breast Cancer Blood. 120: 4316-4316. DOI: 10.1182/Blood.V120.21.4316.4316 |
0.37 |
|
| 2012 |
Komrokji RS, Ali NHA, Mishra A, Corrales-Yepez M, Padron E, Zhang L, Epling-Burnette PK, Little BJ, Pinilla-Ibarz J, Lancet JE, List AF. The Utility of New Prognostic Models in Lower Risk MDS to Identify Patients Who Drive Survival Advantage From Disease Altering Treatment Modalities Blood. 120: 3852-3852. DOI: 10.1182/Blood.V120.21.3852.3852 |
0.393 |
|
| 2012 |
Padron E, Ali NHA, Peker D, Lancet JE, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. Hypomethylating Agents Improve Overall Survival in Higher Risk Chronic Myelomonocytic Leukemia (CMML) Blood. 120: 3838-3838. DOI: 10.1182/Blood.V120.21.3838.3838 |
0.398 |
|
| 2012 |
Komrokji RS, Bally C, Itzykson R, Thepot S, Padron E, Ali NHA, Lancet JE, List AF, Fenaux P, Ades L. Azacitidine Treatment for Lenalidomide (LEN)-Resistant Myelodysplastic Syndrome (MDS) with Del 5q Blood. 120: 3833-3833. DOI: 10.1182/Blood.V120.21.3833.3833 |
0.441 |
|
| 2012 |
Komrokji RS, Corrales-Yepez M, Al Ali NH, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF. Validation of the Lower Risk MD Anderson Prognostic Scoring System for Patients with Myelodysplastic Syndromes Blood. 120: 3826-3826. DOI: 10.1182/Blood.V120.21.3826.3826 |
0.41 |
|
| 2012 |
Seymour JF, Bennett JM, List AF, Mufti GJ, Gore SD, Fenaux P, Santini V, Hetzer J, Songer S, Skikne BS, Beach CL. Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study Blood. 120: 3808-3808. DOI: 10.1182/Blood.V120.21.3808.3808 |
0.438 |
|
| 2012 |
Padron E, Painter JS, Mailloux AW, McGraw KL, McDaniel JM, Bebbington C, Baer M, Yarranton G, Lancet JE, Komrokji RS, List AF, Epling-Burnette P. Preclinical Characterization of KB003, a Novel Humaneered™ Monoclonal Anti-GM-CSF Antibody, Demonstrates That the GM-CSF Signaling Axis Is a Therapeutic Target in Chronic Myelomonocytic Leukemia (CMML) Blood. 120: 3793-3793. DOI: 10.1182/Blood.V120.21.3793.3793 |
0.632 |
|
| 2012 |
Basiorka AA, McGraw KL, Griner LN, Zhang L, De Ceuninck L, Caceres G, Sokol L, Komrokji RS, Wei S, Tavernier J, List AF. Lenalidomide Upregulates Erythropoietin Receptor Expression Through Inhibition of the E3-Ubiquitin Ligase Ring Finger Protein 41 (RNF41) Blood. 120: 3455-3455. DOI: 10.1182/Blood.V120.21.3455.3455 |
0.643 |
|
| 2012 |
McGraw KL, Zhang LM, Fulp W, Lin H, Jerez A, Basiorka AA, Caceres G, Rollison DE, Billingsley D, Kurtin SE, Sokol L, Epling-Burnette P, Mallo M, Sole F, Calasanz MJ, ... ... List AF, et al. Association of MDM2 Gene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome. Blood. 120: 2823-2823. DOI: 10.1182/Blood.V120.21.2823.2823 |
0.654 |
|
| 2012 |
Mishra A, Ali NHA, Corrales-Yepez M, Padron E, Zhang L, Epling-Burnette PK, Kharfan-Dabaja MA, Pinilla-Ibarz J, Little BJ, Lancet JE, List AF, Komrokji RS. Validation of the Revised International Prognostic Scoring System (R-IPSS) for Patients with Myelodysplastic Syndromes: Therapeutic Implications. Blood. 120: 2816-2816. DOI: 10.1182/Blood.V120.21.2816.2816 |
0.353 |
|
| 2012 |
Mishra A, Lancet JE, Ali NHA, Padron E, Ho VQ, Little BJ, Pinilla-Ibarz J, List AF, Komrokji RS. Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure. Blood. 120: 2815-2815. DOI: 10.1182/Blood.V120.21.2815.2815 |
0.41 |
|
| 2012 |
Zhang X, List AF, Komrokji R, Lancet JE, Moscinski L, Zhang L. Overall Survival in Acute Erythroleukemia According to Pathologic Features. Blood. 120: 2597-2597. DOI: 10.1182/Blood.V120.21.2597.2597 |
0.388 |
|
| 2012 |
Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM, Petersdorf S, Godwin JE, Willman CL, Pierce SA, List AF, et al. A Scoring System for Prediction of FLT3-ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood. 120: 2590-2590. DOI: 10.1182/Blood.V120.21.2590.2590 |
0.4 |
|
| 2012 |
Peker D, Padron E, Horna P, Bennett JM, Zhang X, Epling-Burnette PK, Lancet JE, Pinilla J, Moscinski L, List AF, Komrokji RS, Zhang L. A Close Association of History of Autoimmunity with Chronic Myelomonocytic Leukemia (CMML) in Contrast to Chronic Myelogenous Leukemia (CML) Blood. 120: 1712-1712. DOI: 10.1182/Blood.V120.21.1712.1712 |
0.362 |
|
| 2012 |
Padron E, Ali NHA, Peker D, Lancet JE, Epling-Burnette PK, Zhang L, List AF, Komrokji RS. A Comparison of Prognostic Models for Chronic Myelomonocytic Leukemia (CMML) in the Era of Hypomethylating Agents Blood. 120: 1695-1695. DOI: 10.1182/Blood.V120.21.1695.1695 |
0.369 |
|
| 2012 |
Mailloux AW, Sugimori C, Komrokji RS, Maciejewski JP, Sekeres MA, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Abstract 5417: Expansion of effector regulatory T-cells represents a novel and independent prognostic factor marking escape from immune surveillance in Myleodysplastic Syndrome Cancer Research. 72: 5417-5417. DOI: 10.1158/1538-7445.Am2012-5417 |
0.424 |
|
| 2011 |
Vigil CE, Tan W, Wilding GE, Garcia-Manero G, Wang ES, Wetzler M, List AF. Comparison of outcome in erythroleukemia patients treated with standard chemotherapy regimens or hypomethylating agents. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6630. PMID 28020215 DOI: 10.1200/Jco.2011.29.15_Suppl.6630 |
0.406 |
|
| 2011 |
Padron E, Komrokji R, List AF. The 5q- syndrome: biology and treatment. Current Treatment Options in Oncology. 12: 354-68. PMID 21964863 DOI: 10.1007/S11864-011-0165-1 |
0.383 |
|
| 2011 |
Komrokji RS, List AF. Role of lenalidomide in the treatment of myelodysplastic syndromes. Seminars in Oncology. 38: 648-57. PMID 21943671 DOI: 10.1053/J.Seminoncol.2011.04.015 |
0.392 |
|
| 2011 |
Craig BM, Rollison DE, List AF, Cogle CR. Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes. Leukemia Research. 35: 1453-6. PMID 21851978 DOI: 10.1016/J.Leukres.2011.07.028 |
0.375 |
|
| 2011 |
Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, Traina F, Visconte V, Sugimoto Y, Prince C, O'Keefe C, Hsi ED, List A, Sekeres MA, Rao A, McDevitt MA, et al. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 118: 3932-41. PMID 21828135 DOI: 10.1182/Blood-2010-10-311019 |
0.387 |
|
| 2011 |
Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 25: 1808-14. PMID 21760592 DOI: 10.1038/Leu.2011.157 |
0.358 |
|
| 2011 |
Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 117: 2697-702. PMID 21656747 DOI: 10.1002/Cncr.25774 |
0.389 |
|
| 2011 |
Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF. Telomere length in myelodysplastic syndromes. Leukemia & Lymphoma. 52: 1528-36. PMID 21635204 DOI: 10.3109/10428194.2011.568648 |
0.311 |
|
| 2011 |
Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. 118: 523-8. PMID 21551228 DOI: 10.1182/Blood-2011-02-337303 |
0.423 |
|
| 2011 |
Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. The Oncologist. 16: 904-11. PMID 21478277 DOI: 10.1634/Theoncologist.2010-0199 |
0.42 |
|
| 2011 |
Komrokji RS, Sekeres MA, List AF. Management of lower-risk myelodysplastic syndromes: the art and evidence. Current Hematologic Malignancy Reports. 6: 145-53. PMID 21442178 DOI: 10.1007/S11899-011-0086-X |
0.393 |
|
| 2011 |
Bello C, Yu D, Komrokji RS, Zhu W, Wetzstein GA, List AF, Lancet JE. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer. 117: 1463-9. PMID 21425147 DOI: 10.1002/Cncr.25598 |
0.407 |
|
| 2011 |
Sokol L, Caceres G, Volinia S, Alder H, Nuovo GJ, Liu CG, McGraw K, Clark JA, Sigua CA, Chen DT, Moscinski L, Croce CM, List AF. Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. British Journal of Haematology. 153: 24-32. PMID 21332710 DOI: 10.1111/J.1365-2141.2011.08581.X |
0.65 |
|
| 2011 |
Padron E, Komrokji R, List AF. Biology and treatment of the 5q- syndrome. Expert Review of Hematology. 4: 61-9. PMID 21322779 DOI: 10.1586/Ehm.11.2 |
0.365 |
|
| 2011 |
Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A, Kulasekararaj A, Advani AS, Paquette R, List AF, Sekeres MA, McDevitt MA, Mufti GJ, Maciejewski JP. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood. 117: 4552-60. PMID 21285439 DOI: 10.1182/Blood-2010-07-295857 |
0.336 |
|
| 2011 |
Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, List AF, Allen SL, Asatiani E, Mayer LD, Swenson C, Louie AC. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 979-85. PMID 21282541 DOI: 10.1200/Jco.2010.30.5961 |
0.344 |
|
| 2011 |
Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF, Komrokji R. Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e434-6. PMID 21149648 DOI: 10.1200/Jco.2010.31.6265 |
0.315 |
|
| 2011 |
Price SL, Lancet JE, George TJ, Wetzstein GA, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens. Leukemia Research. 35: 301-4. PMID 21109304 DOI: 10.1016/J.Leukres.2010.09.002 |
0.353 |
|
| 2011 |
Sekeres MA, O'Keefe C, List AF, Paulic K, Afable M, Englehaupt R, Maciejewski JP. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. American Journal of Hematology. 86: 102-3. PMID 21080340 DOI: 10.1002/Ajh.21891 |
0.445 |
|
| 2011 |
Ortega J, Komrokji R, List AF. The hematopoietic growth factors in the myelodysplastic syndromes. Cancer Treatment and Research. 157: 363-82. PMID 21052966 DOI: 10.1007/978-1-4419-7073-2_20 |
0.352 |
|
| 2011 |
Kharfan-Dabaja MA, Chavez JC, Yu D, Zhu W, Fernandez-Vertiz EI, Perkins J, Shapiro J, Bookout R, Perez L, Fernandez HF, Komrokji RS, Lancet J, Brand L, Field T, Ayala E, ... ... List AF, et al. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 17: 384-93. PMID 20655389 DOI: 10.1016/J.Bbmt.2010.07.011 |
0.365 |
|
| 2011 |
Yang L, Mailloux AW, Rollison DE, Park J, Painter JS, Komrokji RS, Maciejewski JP, Paquette R, Loughran TP, Wei S, List AF, Epling-Burnette PK. Human Telomerase Reverse Transcriptase (hTERT) Deficiency in Myelodysplastic Syndrome (MDS) Demonstrates Mechanistic Linkage to Aplastic Anemia Pathophysiology Blood. 118: 791-791. DOI: 10.1182/Blood.V118.21.791.791 |
0.347 |
|
| 2011 |
Wei S, Chen X, Zhou J, Zhang L, Fortenbery NR, Rasche SS, McGraw K, Eksioglu EA, Epling-Burnette P, Djeu JY, Gabrilovich DI, List AF. Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC) Blood. 118: 788-788. DOI: 10.1182/Blood.V118.21.788.788 |
0.646 |
|
| 2011 |
Sekeres MA, Komrokji RS, Lancet JE, Tiu RV, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Paquette R, Smith A, Strozniak L, List AF, Maciejewski JP. Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Blood. 118: 607-607. DOI: 10.1182/Blood.V118.21.607.607 |
0.38 |
|
| 2011 |
Mishra A, Rollison DE, Ali NHA, Corrales-Yepez M, Epling-Burnette PK, Lancet JE, List AF, Komrokji RS. Obesity Is Poor Prognostic Factor in Lower Risk Myelodysplastic Syndrome Blood. 118: 5018-5018. DOI: 10.1182/Blood.V118.21.5018.5018 |
0.317 |
|
| 2011 |
Khan AM, Lancet JE, Kharfan-Dabaja MA, Ali NHA, List AF, Komrokji RS. Albumin Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Blood. 118: 4253-4253. DOI: 10.1182/Blood.V118.21.4253.4253 |
0.396 |
|
| 2011 |
Komrokji RS, List AF, Wilhelm F, Lancet JE, Raza A. Oral Formulation of Rigosertib (ON 01910.Na) in Patients with Myelodysplastic Syndrome (MDS) – Phase I Study Results, Blood. 118: 3797-3797. DOI: 10.1182/Blood.V118.21.3797.3797 |
0.328 |
|
| 2011 |
Komrokji RS, Rollison DE, Ali NHA, Corrales-Yepez M, Epling-Burnette PK, Lancet JE, List AF. Tobacco Use Influences Disease Outcome and AML Potential in Myelodysplastic Syndromes Blood. 118: 3790-3790. DOI: 10.1182/Blood.V118.21.3790.3790 |
0.317 |
|
| 2011 |
Lancet JE, List AF, Bello CM, Ali NHA, Komrokji RS. Outcomes and Prognostic Factors Following Double-Induction Chemotherapy in AML – A Large, Single Institutional Experience, Blood. 118: 3605-3605. DOI: 10.1182/Blood.V118.21.3605.3605 |
0.409 |
|
| 2011 |
Komrokji RS, Khan AM, Ali NHA, List AF, Lancet JE. Impact of Red Blood Cell (RBC) Transfusion During Induction Chemotherapy in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) Blood. 118: 3600-3600. DOI: 10.1182/Blood.V118.21.3600.3600 |
0.407 |
|
| 2011 |
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. A Mechanistic Rationale for the Use of Statins to Enhance JAK Inhibitor Therapy in MPNs Blood. 118: 2816-2816. DOI: 10.1182/Blood.V118.21.2816.2816 |
0.643 |
|
| 2011 |
Komrokji RS, Ali NHA, Corrales-Yepez M, Padron E, Epling-Burnette PK, Lancet JE, List AF. Impact of Iron Overload in Higher Risk Myelodysplastic Syndromes Blood. 118: 2777-2777. DOI: 10.1182/Blood.V118.21.2777.2777 |
0.384 |
|
| 2011 |
Komrokji RS, Ali NHA, Padron E, Lancet JE, List AF. Impact of Iron Chelation Therapy on Overall Survival and AML Transformation in Lower Risk MDS Patients Treated At the Moffitt Cancer Center Blood. 118: 2776-2776. DOI: 10.1182/Blood.V118.21.2776.2776 |
0.416 |
|
| 2011 |
Komrokji RS, Ali NHA, Padron E, Lancet JE, List AF. Azacitidine Treatment of Lenalidomide-Resistant Myelodysplastic Syndrome with Deletion 5q Blood. 118: 2774-2774. DOI: 10.1182/Blood.V118.21.2774.2774 |
0.454 |
|
| 2011 |
Komrokji RS, Pinilla-Ibarz J, Yu D, Nardelli L, Cubitt C, Zhao X, Fernandez HF, List AF, Lancet JE. A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in relapsed or Refractory Acute Myeloid Leukemia Blood. 118: 2604-2604. DOI: 10.1182/Blood.V118.21.2604.2604 |
0.431 |
|
| 2011 |
Lancet JE, Komrokji RS, Yu D, Advani AS, Searles T, Sekeres MA, List AF. A Phase 1 Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Blood. 118: 2600-2600. DOI: 10.1182/Blood.V118.21.2600.2600 |
0.377 |
|
| 2011 |
Jaglal MV, Duong VH, Bello CM, Ali NHA, Fernandez HF, Lancet JE, List AF, Komrokji RS. Efficacy of Cladribine, Cytarabine, G-CSF (Neupogen), Mitoxantrone (CLAG-M Regimen) Compared to Standard 3+7 (Anthracycline and Cytarabine) in Secondary Acute Myeloid Leukemia (sAML) After Azanucleosides Failure Blood. 118: 256-256. DOI: 10.1182/Blood.V118.21.256.256 |
0.333 |
|
| 2011 |
Painter JS, Park J, Clemente MJ, O'Keefe CL, Wei S, Maciejewski JP, Paquette R, Loughran TP, List AF, Epling-Burnette PK. Increased Group B Killer Cell Immunoglobulin-Like Receptor (KIR) Haplotypes with Mismatched MHC Class I and Altered NK Repertoire Distribution in Bone Marrow Failure Syndromes Blood. 118: 2412-2412. DOI: 10.1182/Blood.V118.21.2412.2412 |
0.352 |
|
| 2011 |
Basiorka AA, McGraw K, Clark J, Caceres G, Johnson J, Hall L, Sokol L, Wei S, List AF. Lenalidomide Upregulates Erythropoietin Receptor Expression in Hematopoietic Progenitors by Modulating Receptor Turnover Blood. 118: 2382-2382. DOI: 10.1182/Blood.V118.21.2382.2382 |
0.632 |
|
| 2011 |
Duong VH, Jaglal MV, Zhang L, Kale V, Lancet JE, Komrokji RS, List AF. Phase II Pilot Study of Oral Dasatinib in Subjects with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed Conventional Therapy Blood. 118: 1727-1727. DOI: 10.1182/Blood.V118.21.1727.1727 |
0.44 |
|
| 2011 |
Ades L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, Maciejewski JP, Dreyfus F, List AF, Fenaux P, Komrokji RS. Prognostic Factors of Response and Survival in CMML Patients Treated with Azacitidine (AZA) Blood. 118: 1726-1726. DOI: 10.1182/Blood.V118.21.1726.1726 |
0.371 |
|
| 2011 |
Powers J, Padron E, Dubovsky J, Berchmans E, Farnum T, Bai F, Sahakian E, Ahmed J, Komrokji RS, Lancet JE, List AF, McNeel DG, Dessureault S, Antonia S, Sotomayor EM, et al. Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome Blood. 118: 1725-1725. DOI: 10.1182/Blood.V118.21.1725.1725 |
0.328 |
|
| 2011 |
Fenaux P, Giagounidis A, List AF, Nimer SD, Hellström-Lindberg E, Powell BL, Yu X, Skikne B, Shammo JM, Cañizo Cd. Outcomes for Patients (Pts) with Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) with del5q Aged < 65 Years Treated with Lenalidomide (LEN) in MDS-003 and MDS-004: A Retrospective Combined Analysis Blood. 118: 1723-1723. DOI: 10.1182/Blood.V118.21.1723.1723 |
0.325 |
|
| 2011 |
Padron E, Painter JS, Mailloux AW, McDaniel JM, Bebbington C, Baer M, Komrokji RS, List AF, Epling-Burnette PK. GM-CSF Signaling Abnormalities in Chronic Myelomonocytic Leukemia Blood. 118: 1713-1713. DOI: 10.1182/Blood.V118.21.1713.1713 |
0.362 |
|
| 2011 |
Komrokji RS, Ali NHA, Alrawi E, Padron E, Perkins J, Field T, Lancet JE, List AF. Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome Blood. 118: 1712-1712. DOI: 10.1182/Blood.V118.21.1712.1712 |
0.443 |
|
| 2011 |
Giagounidis A, Raza A, List AF, Fenaux P, Benettaib B, Brown B, Zhong J, Brandenburg N, Mufti GJ. Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes Blood. 118: 1704-1704. DOI: 10.1182/Blood.V118.21.1704.1704 |
0.413 |
|
| 2011 |
Mailloux AW, Sugimori C, Komrokji RS, Maciejewski JP, Paquette R, Loughran TP, List AF, Epling-Burnette PK. A Switch in Regulatory T-Cell Memory Phenotype Is Associated with Poor Survival in Lower Risk Myleodysplastic Syndrome Patients Blood. 118: 1703-1703. DOI: 10.1182/Blood.V118.21.1703.1703 |
0.36 |
|
| 2011 |
Makishima H, Jankowska AM, Visconte V, Tiu RV, Guinta KM, Szpurka H, Sugimoto Y, O'Keefe CL, List AF, Sekeres MA, McDevitt MA, Maciejewski JP. Spliceosome GENE MUTATIONS ARE Also PRESENT In the Diverse Mutational Spectrum of CHRONIC Myelomonocytic LEUKEMIA Blood. 118: 1402-1402. DOI: 10.1182/Blood.V118.21.1402.1402 |
0.345 |
|
| 2011 |
Kuendgen A, Lauseker M, List AF, Fenaux P, Giagounidis A, Brandenburg N, Backstrom J, Glasmacher A, Hasford J, Germing U. Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study Blood. 118: 119-119. DOI: 10.1182/Blood.V118.21.119.119 |
0.384 |
|
| 2011 |
Komrokji RS, List AF, Khoury HJ, Lancet JE, Jabbour E, Foudray MC, Winski SL, Bell S, Rush SA, Maloney L, Ptaszynski AM, Kantarjian HM, Garcia-Manero G. Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes Blood. 118: 118-118. DOI: 10.1182/Blood.V118.21.118.118 |
0.347 |
|
| 2011 |
McDaniel JM, Zou J, List AF, Epling-Burnette PK. CD8+ CD28null T Cell Expansion Impairs Lenalidomide Immunomodulatory Function in Myelodysplastic Syndrome Blood. 118: 1117-1117. DOI: 10.1182/Blood.V118.21.1117.1117 |
0.353 |
|
| 2011 |
Wei S, Chen X, McGraw K, Zhou J, Burnette P, Wang H, Djeu J, Gabrilovich D, List A. 39 Myeloid-derived suppressor cells (MDSC) are effectors of bone marrow suppression in lower risk myelodysplastic syndromes (MDS) Leukemia Research. 35: S13. DOI: 10.1016/S0145-2126(11)70041-8 |
0.641 |
|
| 2011 |
Field T, Perkins J, Nishihori T, Pidala J, Tomblyn M, Fernandez H, Perez L, Kharfan-Dabaja M, Komrokji R, Lancet J, Ayala E, Alsina M, Ochoa L, Kim J, List A, et al. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: Comparison of Survival in Patients With an Available Donor Compared to Patients Without a Donor in Patients Up to Age 75 Biology of Blood and Marrow Transplantation. 17: S300. DOI: 10.1016/J.Bbmt.2010.12.439 |
0.368 |
|
| 2010 |
Sugimori C, List AF, Epling-Burnette PK. Immune dysregulation in myelodysplastic syndrome. Hematology Reports. 2: e1. PMID 22184512 DOI: 10.4081/Hr.2010.E1 |
0.379 |
|
| 2010 |
Hartley MA, Sokol L, Caceres G, Hussein MA, List A, Pinilla-Ibarz J. Monoclonal gammopathy of undetermined significance disguised as chronic neutrophilic leukemia. Mediterranean Journal of Hematology and Infectious Diseases. 2: e2010002. PMID 21415944 DOI: 10.4084/Mjhid.2010.002 |
0.301 |
|
| 2010 |
Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, Astrand-Grundström I, Strömbeck B, Horvat A, Ferry H, Dhanda RS, Hast R, Rydén T, Vyas P, Göhring G, ... ... List A, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. The New England Journal of Medicine. 363: 1025-37. PMID 20825315 DOI: 10.1056/Nejmoa0912228 |
0.385 |
|
| 2010 |
Makishima H, Jankowska AM, Tiu RV, Szpurka H, Sugimoto Y, Hu Z, Saunthararajah Y, Guinta K, Keddache MA, Putnam P, Sekeres MA, Moliterno AR, List AF, McDevitt MA, Maciejewski JP. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 24: 1799-804. PMID 20724984 DOI: 10.1038/Leu.2010.167 |
0.349 |
|
| 2010 |
Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Critical Reviews in Oncology/Hematology. 76: 218-27. PMID 20451404 DOI: 10.1016/J.Critrevonc.2010.04.005 |
0.382 |
|
| 2010 |
Komrokji RS, Lancet JE, List AF. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more? Current Hematologic Malignancy Reports. 5: 9-14. PMID 20425391 DOI: 10.1007/S11899-009-0036-Z |
0.392 |
|
| 2010 |
Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. European Journal of Haematology. 85: 130-8. PMID 20394651 DOI: 10.1111/J.1600-0609.2010.01456.X |
0.427 |
|
| 2010 |
Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematology/Oncology Clinics of North America. 24: 377-88. PMID 20359632 DOI: 10.1016/J.Hoc.2010.02.013 |
0.429 |
|
| 2010 |
Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Ganetsky R, Latham D, Paulic K, Afable M, Saba HI, Loughran TP, Maciejewski JP. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2253-8. PMID 20354132 DOI: 10.1200/Jco.2009.26.0745 |
0.409 |
|
| 2010 |
Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U, Gore SD, Ramos F, Beyne-Rauzy O, List A, McKenzie D, Backstrom J, Beach CL. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. British Journal of Haematology. 149: 244-9. PMID 20136825 DOI: 10.1111/J.1365-2141.2010.08082.X |
0.398 |
|
| 2010 |
List AF. Iron overload in myelodysplastic syndromes: diagnosis and management. Cancer Control : Journal of the Moffitt Cancer Center. 17: 2-8. PMID 20125080 DOI: 10.1177/107327481001701S01 |
0.327 |
|
| 2010 |
Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 562-9. PMID 20026804 DOI: 10.1200/Jco.2009.23.8329 |
0.416 |
|
| 2010 |
Pal R, Monaghan SA, Hassett AC, Mapara MY, Schafer P, Roodman GD, Ragni MV, Moscinski L, List A, Lentzsch S. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood. 115: 605-14. PMID 19965623 DOI: 10.1182/Blood-2009-05-221077 |
0.344 |
|
| 2010 |
Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B. Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis. Haematologica. 95: 340-2; author reply . PMID 19850902 DOI: 10.3324/Haematol.2009.017764 |
0.319 |
|
| 2010 |
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen IM, Willman CL, Kopecky KJ, Appelbaum FR. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. British Journal of Haematology. 148: 48-58. PMID 19821823 DOI: 10.1111/J.1365-2141.2009.07919.X |
0.36 |
|
| 2010 |
Sokol L, Caceres G, Rocha K, Stockero KJ, Dewald DW, List AF. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones. Leukemia Research. 34: 821-3. PMID 19819015 DOI: 10.1016/J.Leukres.2009.09.016 |
0.377 |
|
| 2010 |
Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 45: 255-60. PMID 19543327 DOI: 10.1038/Bmt.2009.134 |
0.382 |
|
| 2010 |
Komrokji RS, Matacia-Murphy GM, Al Ali NH, Beg MS, Safa MM, Rollison DE, List AF. Outcome of patients with myelodysplastic syndromes in the Veterans Administration population. Leukemia Research. 34: 59-62. PMID 19368972 DOI: 10.1016/J.Leukres.2009.03.022 |
0.354 |
|
| 2010 |
Sugimori C, Shain K, Caceres G, Sokol L, Araten D, Paquette R, O'Keefe C, Maciejewski J, Epling-Burnette PK, List AF. Co-existence of JAK V617F and PIG-A mutations in primary Budd-Chiari syndrome F1000research. 1. DOI: 10.7490/F1000Research.185.1 |
0.315 |
|
| 2010 |
Roboz GJ, Lancet JE, Cripe LD, Ravandi Kashani F, List AF, Fox JA, Michelson G, Karp JE. Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology. 28: 6526-6526. DOI: 10.1200/Jco.2010.28.15_Suppl.6526 |
0.305 |
|
| 2010 |
McGraw KR, Zhang LM, Rollison DE, Lin H, Rawal B, Billingsley D, Kurtin SE, Caceres G, Clark J, Sokol L, Epling-Burnette PK, Guinta K, Maciejewski JP, Mallo M, Solé F, ... ... List AF, et al. Predisposition to Myelodysplastic Syndrome with Deletion 5q Is Associated with TP53 Codon 72 Genotype Blood. 116: 612-612. DOI: 10.1182/Blood.V116.21.612.612 |
0.411 |
|
| 2010 |
Jankowska A, Makishima H, Tiu RV, Szpurka H, Huang Y, Sugimoto Y, Prince C, O'Keefe CL, Hsi E, List AF, Sekeres MA, Rao A, McDevitt MA, Maciejewski JP. Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2 Blood. 116: 611-611. DOI: 10.1182/Blood.V116.21.611.611 |
0.37 |
|
| 2010 |
Makishima H, Jankowska A, Tiu RV, Szpurka H, Sugimoto Y, Ebrahem Q, Hu Z, Mahfouz R, Saunthararajah Y, Guinta K, Keddache M, O'Keefe CL, Sekeres MA, List AF, McDevitt MA, et al. Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies Blood. 116: 607-607. DOI: 10.1182/Blood.V116.21.607.607 |
0.367 |
|
| 2010 |
Epling-Burnette P, Komrokji RS, Maciejewski JP, Sekeres MA, Paquette R, Wei S, Painter JS, Bai F, Fulp WJ, Paleveda-Pena J, Chen D, List AF. Phase 2 Multicenter Trial of Rabbit Anti-Thymocyte Serotherapy In Myelodysplastic Syndrome: Rate of Hematological Improvement Associated with Pre-Treatment Disease Duration Blood. 116: 602-602. DOI: 10.1182/Blood.V116.21.602.602 |
0.445 |
|
| 2010 |
Corrales-Yepez M, Lancet JE, List AF, Kharfan-Dabaja MA, Field T, Padron E, Komrokji RS. Validation of the Newly Proposed MD Anderson Prognostic Risk Model for Patients with Myelodysplastic Syndromes Blood. 116: 444-444. DOI: 10.1182/Blood.V116.21.444.444 |
0.379 |
|
| 2010 |
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. Requirement of Lipid Raft Integrity for Signaling by JAK2-V617F Blood. 116: 4191-4191. DOI: 10.1182/Blood.V116.21.4191.4191 |
0.624 |
|
| 2010 |
Teichman ML, Wetzstein GA, Ho VQ, Lancet JE, List AF, Komrokji RS. Efficacy of Azacitidine In the Treatment of Chronic Myelomonocytic Leukemia Blood. 116: 4017-4017. DOI: 10.1182/Blood.V116.21.4017.4017 |
0.41 |
|
| 2010 |
Sugimoto Y, Sekeres MA, Makishima H, O'Keefe CL, Guinta K, Afable M, McGraw KR, List AF, Maciejewski J. Cytogenetic Predictors of Response to Lenalidomide In Myeloid Malignancies without Del(5q) Blood. 116: 4016-4016. DOI: 10.1182/Blood.V116.21.4016.4016 |
0.382 |
|
| 2010 |
Corrales-Yepez M, Kharfan-Dabaja MA, Lancet J, List AF, Padron E, Rollison D, Epling-Burnette P, Zhang L, Field T, Pinilla-Ibarz J, Komrokji RS. Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes Blood. 116: 4001-4001. DOI: 10.1182/Blood.V116.21.4001.4001 |
0.374 |
|
| 2010 |
Reljic T, Bhansali N, Komrokji RS, Lin K, List AF, Djulbegovic B, Fenstermacher DA, Lancet JE, Miladinovic B, Kumar A. Comparative Effectiveness of Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndromes Blood. 116: 3995-3995. DOI: 10.1182/Blood.V116.21.3995.3995 |
0.41 |
|
| 2010 |
Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld JL, Mulford D, Norwood T, Willman CL, List AF, Appelbaum FR. A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605) Blood. 116: 332-332. DOI: 10.1182/Blood.V116.21.332.332 |
0.397 |
|
| 2010 |
Yang L, Schmidt A, Komrokji R, Painter JS, Cole A, List AF, Rollison DE, Epling-Burnette PK. Importance of T-Cell Proliferative Stress In Myelodysplastic Syndrome Blood. 116: 2939-2939. DOI: 10.1182/Blood.V116.21.2939.2939 |
0.336 |
|
| 2010 |
Sekeres MA, Narang M, Komrokji RS, Maciejewski JP, List AF, Street TK, Swern AS, Sullivan KA, Grinblatt DL. Therapeutic Response to Azacitidine (AZA) In Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled In the AVIDA Registry Blood. 116: 2931-2931. DOI: 10.1182/Blood.V116.21.2931.2931 |
0.369 |
|
| 2010 |
Padron E, Komrokji RS, Lancet JE, List AF, Dessureault S, Antonia S, Ahmed J, Patel S, Powers J, Bai F, Sotomayor EM, Epling-Burnette P, Pinilla-Ibarz J. A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS) Blood. 116: 2925-2925. DOI: 10.1182/Blood.V116.21.2925.2925 |
0.384 |
|
| 2010 |
Lin K, Reljic T, Kumar A, Lancet JE, List AF, Komrokji RS. Poor Outcome of Patients with Myelodysplastic Syndrome (MDS) After Azacitidine Treatment Failure Blood. 116: 2913-2913. DOI: 10.1182/Blood.V116.21.2913.2913 |
0.411 |
|
| 2010 |
Palath V, Vekhande R, Baer M, Ching W, Tomasevic N, Martinez D, Yi C, Bhaskar S, Luehrsen K, Williams J, Leung J, List AF, Zhang L, Lackmann M, Boyd A, et al. A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples Blood. 116: 2897-2897. DOI: 10.1182/Blood.V116.21.2897.2897 |
0.337 |
|
| 2010 |
McDaniel JM, Daniel KG, Luhder F, Wei S, Tanner R, Grams D, List AF, Epling-Burnette PK. Virtual and Physical Analysis of the Proximal T Cell Signalosome Reveals PP2A Inhibition Is Important for Co-Stimulatory Function of Immunomodulatory (IMiD) Drugs Blood. 116: 281-281. DOI: 10.1182/Blood.V116.21.281.281 |
0.309 |
|
| 2010 |
Mailloux AW, Bai F, Zhang L, Padron E, Yang L, Wei C, Schmidt A, Sokol L, Chen D, Loughran TP, List AF, Epling-Burnette PK. Altered Collagen Production by Dysfunctional Mesenchymal Stem Cells Is Linked to T Cell Large Granular Lymphocyte Leukemia Pathophysiology. Blood. 116: 2595-2595. DOI: 10.1182/Blood.V116.21.2595.2595 |
0.359 |
|
| 2010 |
Field T, Perkins J, Nishihori T, Pidala J, Fernandez HF, Tomblyn M, Kharfan-Dabaja M, Perez L, Lancet JE, Komrokji RS, ochoa-Bayona J, Alsina M, Ayala E, Kim J, List AF, et al. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor Blood. 116: 2381-2381. DOI: 10.1182/Blood.V116.21.2381.2381 |
0.368 |
|
| 2010 |
George TJ, Woolery JE, Wetzstein GA, Ho VQ, Lancet JE, List AF, Komrokji RS. A Retrospective Study of Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia: Lack of Response Observed In a Heavily Pretreated Population Blood. 116: 2186-2186. DOI: 10.1182/Blood.V116.21.2186.2186 |
0.43 |
|
| 2010 |
Komrokji RS, Lancet JE, Yu D, Santana E, Yan L, Smith PS, Tinsley S, Deaver D, Zhang L, List AF. Erlotinib for Treatment of Myelodysplastic Syndromes: A Phase II Clinical Study Blood. 116: 1854-1854. DOI: 10.1182/Blood.V116.21.1854.1854 |
0.447 |
|
| 2010 |
Pogosova-Agadjanyan EL, Kopecky KJ, Lee H, Anderson JE, Godwin JE, List AF, Meshinchi S, Oehler V, Petersdorf SH, Willman CL, Appelbaum FR, Radich JP, Stirewalt DL. Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients. Blood. 116: 1679-1679. DOI: 10.1182/Blood.V116.21.1679.1679 |
0.44 |
|
| 2010 |
Field T, Perkins J, Nishihori T, Pidala J, Fernandez HF, Tomblyn M, Kharfan-Dabaja M, Perez L, Komrokji RS, Lancet JE, Kim J, Ayala E, Alsina M, ochoa-Bayona J, List AF, et al. Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML Blood. 116: 1333-1333. DOI: 10.1182/Blood.V116.21.1333.1333 |
0.37 |
|
| 2010 |
O'Keefe CL, Sugimori C, Afable M, Clemente M, Shain K, Araten D, List AF, Epling-Burnette PK, Maciejewski J. Deletions of Xp22.2 Including PIG-A Locus Lead to Paroxysmal Nocturnal Hemoglobinuria. Blood. 116: 1158-1158. DOI: 10.1182/Blood.V116.21.1158.1158 |
0.416 |
|
| 2010 |
Field T, Perkins J, Kim J, Kharfan-Dabaja M, Fenandez H, Perez L, Lancet J, Komrokji R, Ochoa-Bayona L, Alsina M, List A, Anasetti C. Evaluation Of Patients With Myelodysplastic Syndrome (MDS) Up To Age Seventy-Five, Referred For Allogeneic Hematopoietic Cell Transplant (HCT) Including Donor Availability And HCT Outcomes Biology of Blood and Marrow Transplantation. 16: S158-S159. DOI: 10.1016/J.Bbmt.2009.12.023 |
0.331 |
|
| 2009 |
Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6109-16. PMID 19901108 DOI: 10.1200/Jco.2009.23.7503 |
0.371 |
|
| 2009 |
List A. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes. Clinical Lymphoma & Myeloma. 9: S302-4. PMID 19778857 DOI: 10.3816/Clm.2009.S.028 |
0.424 |
|
| 2009 |
Szende A, Schaefer C, Goss TF, Heptinstall K, Knight R, Lübbert M, Deschler B, Fenaux P, Mufti GJ, Killick S, List AF. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health and Quality of Life Outcomes. 7: 81. PMID 19737399 DOI: 10.1186/1477-7525-7-81 |
0.328 |
|
| 2009 |
Kurtin SE, List AF. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide. Clinical Lymphoma & Myeloma. 9: E10-3. PMID 19525184 DOI: 10.3816/Clm.2009.N.053 |
0.41 |
|
| 2009 |
Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, Byrd J, Sokol L, Lawrence N, Pireddu R, Dewald G, Williams A, Maciejewski J, List A. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proceedings of the National Academy of Sciences of the United States of America. 106: 12974-9. PMID 19470455 DOI: 10.1073/Pnas.0811267106 |
0.375 |
|
| 2009 |
Epling-Burnette PK, List AF. Advancements in the molecular pathogenesis of myelodysplastic syndrome. Current Opinion in Hematology. 16: 70-6. PMID 19468267 DOI: 10.1097/Moh.0B013E3283257Ac7 |
0.349 |
|
| 2009 |
Raza A, Galili N, Smith S, Godwin J, Lancet J, Melchert M, Jones M, Keck JG, Meng L, Brown GL, List A. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood. 113: 6533-40. PMID 19398716 DOI: 10.1182/Blood-2009-01-176032 |
0.349 |
|
| 2009 |
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet. Oncology. 10: 223-32. PMID 19230772 DOI: 10.1016/S1470-2045(09)70003-8 |
0.366 |
|
| 2009 |
Wei S, Chen X, Rocha K, Qi D, Tao J, Gjertsen N, Zhou J, Liu J, Gabrilovich D, Epling-Burnette PK, Djeu JY, List AF. Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS). Blood. 114: 597-597. DOI: 10.1182/Blood.V114.22.597.597 |
0.368 |
|
| 2009 |
Cogle CR, Cole A, Imanirad I, Kamat L, Yu D, List AF, Rollison DE. A Keyword Search Strategy to Identify Missed Cases of Myelodysplastic Syndromes in Population-Based Cancer Registries. Blood. 114: 4852-4852. DOI: 10.1182/Blood.V114.22.4852.4852 |
0.303 |
|
| 2009 |
Komrokji RS, Kharfan-Dabaja MA, Price SL, Wetzstein GA, List AF, Fernandez HF, George TJ, Pinilla-Ibarz J, Ho VQ, Lancet JE. Albumin Is a Prognostic Factor for Response and Overall Survival in Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood. 114: 4685-4685. DOI: 10.1182/Blood.V114.22.4685.4685 |
0.382 |
|
| 2009 |
List AF, Mathias S, Crosby RD, Heptinstall K, Cella D. Disease Burden and Treatment Impact Associated with Myelodysplastic Syndromes: Preliminary Findings From a Web-Based Survey. Blood. 114: 4522-4522. DOI: 10.1182/Blood.V114.22.4522.4522 |
0.32 |
|
| 2009 |
List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa EC. Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study. Blood. 114: 3829-3829. DOI: 10.1182/Blood.V114.22.3829.3829 |
0.34 |
|
| 2009 |
Sekeres MA, Maciejewski JP, Donley DW, Grinblatt DL, Narang M, Malone JM, Komrokji RS, List AF, Baker JG, Sweet DA, Sullivan KA. A Study Comparing Dosing Regimens and Efficacy of Subcutaneous to Intravenous Azacitidine (AZA) for the Treatment of Myelodysplastic Syndromes (MDS). Blood. 114: 3797-3797. DOI: 10.1182/Blood.V114.22.3797.3797 |
0.376 |
|
| 2009 |
Field T, Perkins J, Kharfan-Dabaja MA, Fernandez HF, Perez L, Ochoa-Bayona JL, Lancet JE, Komrokji RS, Alsina M, Ayala E, List AF, Anasetti C. Evaluation of 243 Patients with Myelodysplastic Syndrome (MDS) Referred for Hematopoietic Cell Transplant (HCT) Including Donor Availability and HCT Outcomes. Blood. 114: 3383-3383. DOI: 10.1182/Blood.V114.22.3383.3383 |
0.329 |
|
| 2009 |
Sugimori C, Shain KH, Caceres G, Sokol L, Araten D, Maciejewski JP, Zou J, Epling-Burnette PK, List AF. Co-Existance of JAK V617F and PIG-A mutations in Primary Budd-Chiari Syndrome. Blood. 114: 3193-3193. DOI: 10.1182/Blood.V114.22.3193.3193 |
0.395 |
|
| 2009 |
List AF, Rocha K, Zhang L, Komrokji RS, Clark J, Caceres G, Billingsley D, Sokol L, Lancet JE, Maciejewski JP, Sekeres MA, Chen X, Wei S. Secondary Resistance to Lenalidomide in Del(5q) MDS Is Associated with CDC25C & PP2A Overexpression. Blood. 114: 292-292. DOI: 10.1182/Blood.V114.22.292.292 |
0.403 |
|
| 2009 |
Epling-Burnette PK, List AF, Clark J, Lee J, Jonathan KA, Fulp W, Li X, Zheng W, Painter JS, Zou J, Komrokji RS, Wei S, Park J, Schmidt A, Sugimori C, et al. Pathogenetic Role of Impaired Telomere Repair in Myelodysplastic Syndrome. Blood. 114: 2777-2777. DOI: 10.1182/Blood.V114.22.2777.2777 |
0.354 |
|
| 2009 |
Vigil C, Cortes J, Kantarjian HM, Garcia-Manero G, Lancet JE, List AF. Hypomethylating Therapy for the Treatment of Acute Erythroleukemia Patients. Blood. 114: 2069-2069. DOI: 10.1182/Blood.V114.22.2069.2069 |
0.427 |
|
| 2009 |
Wetzstein GA, George TJ, Sharifi M, Hoang VD, Ho VQ, Quilitz RE, Spears DA, Komrokji RS, List AF, Lancet JE, Greene JN. Comparable Efficacy and Safety with Voriconazole or Posaconazole as Primary Antifungal Prophylaxis in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy. Blood. 114: 2059-2059. DOI: 10.1182/Blood.V114.22.2059.2059 |
0.39 |
|
| 2009 |
Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R. Perceptions of Disease State, Treatment Expectations, and Prognosis Among Patients with Myelodysplastic Syndromes. Blood. 114: 1771-1771. DOI: 10.1182/Blood.V114.22.1771.1771 |
0.331 |
|
| 2009 |
Epling-Burnette P, Zou J, Painter JS, Chen D, Fulp J, Komrokji RS, Wei S, List AF. Functional T Cell Array Reveals Pre-Treatment Expanded Terminal Effector Memory Response Is Associated with Lenalidomide Failure in Non-Del(5q) Myelodysplastic Syndrome. Blood. 114: 1759-1759. DOI: 10.1182/Blood.V114.22.1759.1759 |
0.372 |
|
| 2009 |
Palath V, Vekhande R, Lee A, Williams J, Zhang L, List AF, Boyd A, Lackmann M, Scott AM, Cilloni D, Yarranton GT, Bebbington C. A Recombinant Human Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Shows Selective Cytotoxicity against Myeloid Leukemia Cells and CD123-Positive Leukemic Stem Cells. Blood. 114: 1728-1728. DOI: 10.1182/Blood.V114.22.1728.1728 |
0.33 |
|
| 2009 |
Schmidt A, Komrokji RS, Painter JS, Rollison DE, Zhang L, Moscinski LC, List AF, Epling-Burnette PK. Positive Impact of T-Cell Clonal Expansion On Overall Survival in Patients with High-Risk Myelodysplastic Syndromes. Blood. 114: 1572-1572. DOI: 10.1182/Blood.V114.22.1572.1572 |
0.389 |
|
| 2009 |
Lancet JE, Komrokji RS, Lin H, Castro CMd, Rizzieri DA, Melchert M, List AF. Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission. Blood. 114: 1029-1029. DOI: 10.1182/Blood.V114.22.1029.1029 |
0.396 |
|
| 2009 |
Price SL, George TJ, Wetzstein GA, Lancet JE, List AF, Ho VQ, Fernandez HF, Pinilla-Ibarz J, Kharfan-Dabaja MA, Komrokji RS. Salvage Chemotherapy Regimens for Acute Myeloid Leukemia: Is One Better?. Blood. 114: 1022-1022. DOI: 10.1182/Blood.V114.22.1022.1022 |
0.395 |
|
| 2008 |
Lancet JE, Yu J, Saba H, Lush R, Schmidt M, Wride K, Knight R, List AF. Erythroid response to lenalidomide (LEN) + recombinant erythropoietin (EPO) and endogenous serum EPO concentration in MDS cytokine-failures. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7031. PMID 27950011 DOI: 10.1200/Jco.2008.26.15_Suppl.7031 |
0.314 |
|
| 2008 |
Brandenburg NA, Weiss L, Bwire R, Schmidt M, Knight R, List AF. Venous thromboembolism in patients with myelodysplastic syndrome treated with lenalidomide: Incidence and risk factors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 7084. PMID 27949569 DOI: 10.1200/Jco.2008.26.15_Suppl.7084 |
0.352 |
|
| 2008 |
Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LB. Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update. Ecancermedicalscience. 2: 121. PMID 22275991 DOI: 10.3332/Ecancer.2008.121 |
0.369 |
|
| 2008 |
Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, McKenzie D, Beach CL. The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update. Ecancermedicalscience. 2: 118. PMID 22275990 DOI: 10.3332/Ecancer.2008.118 |
0.375 |
|
| 2008 |
Haferlach C, Bacher U, Tiu R, Maciejewski JP, List A. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing. Cancer Genetics and Cytogenetics. 187: 101-11. PMID 19027491 DOI: 10.1016/J.Cancergencyto.2008.08.002 |
0.374 |
|
| 2008 |
Sekeres MA, Maciejewski JP, Giagounidis AA, Wride K, Knight R, Raza A, List AF. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5943-9. PMID 19018091 DOI: 10.1200/Jco.2007.15.5770 |
0.434 |
|
| 2008 |
Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, Maciejewski JP. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. Journal of the National Cancer Institute. 100: 1542-51. PMID 18957672 DOI: 10.1093/Jnci/Djn349 |
0.372 |
|
| 2008 |
Navas T, Zhou L, Estes M, Haghnazari E, Nguyen AN, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins LS, Platanias LC, List A, Verma A, Bhagat T, Gajavelli S, et al. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leukemia & Lymphoma. 49: 1963-75. PMID 18949619 DOI: 10.1080/10428190802322919 |
0.339 |
|
| 2008 |
List AF. Treatment strategies to optimize clinical benefit in the patient with myelodysplastic syndromes. Cancer Control : Journal of the Moffitt Cancer Center. 15: 29-39. PMID 18813207 DOI: 10.1177/107327480801504S04 |
0.372 |
|
| 2008 |
Kantarjian H, O'Brien S, Ravandi F, Cortes J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, Freireich EJ, Garcia-Manero G. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 113: 1351-61. PMID 18618511 DOI: 10.1002/Cncr.23697 |
0.381 |
|
| 2008 |
Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O'Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, Martinelli G, Nielsen JL, Petersdorf S, ... ... List A, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 22: 1707-11. PMID 18548095 DOI: 10.1038/Leu.2008.156 |
0.428 |
|
| 2008 |
Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 112: 45-52. PMID 18443215 DOI: 10.1182/Blood-2008-01-134858 |
0.308 |
|
| 2008 |
Knop S, Einsele H, Bargou R, Cosgrove D, List A. Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment. Leukemia & Lymphoma. 49: 346-9. PMID 18231924 DOI: 10.1080/10428190701799027 |
0.341 |
|
| 2008 |
Melchert M, List A. Targeted therapies in myelodysplastic syndrome. Seminars in Hematology. 45: 31-8. PMID 18179967 DOI: 10.1053/J.Seminhematol.2007.10.001 |
0.341 |
|
| 2008 |
Ozawa Y, Williams AH, Estes ML, Matsushita N, Boschelli F, Jove R, List AF. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leukemia Research. 32: 893-903. PMID 18179820 DOI: 10.1016/J.Leukres.2007.11.032 |
0.311 |
|
| 2008 |
Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, ... ... List AF, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 111: 86-93. PMID 17893227 DOI: 10.1182/Blood-2007-01-068833 |
0.42 |
|
| 2008 |
Sekeres MA, List AF. Active Treatment Strategies Improving Outcomes in Patients with Myelodysplastic Syndromes with the Deletion 5q Abnormality Clinical Leukemia. 2: 28-33. DOI: 10.3816/Clk.2008.N.003 |
0.447 |
|
| 2008 |
Shah NP, Olszynski P, Sokol L, Verstovsek S, Hoffman R, List AF, Cortes J, Kantarjian HM, Gilliland DG, Clary DO, Bui LA, Wadleigh M. A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Blood. 112: 98-98. DOI: 10.1182/Blood.V112.11.98.98 |
0.396 |
|
| 2008 |
Pal R, Roodman GD, Mapara M, Mocsinski L, List AF, Lentzsch S. Immunomodulatory Derivatives of Thalidomide (IMiD)-Induced Neutropenia Is Associated with PU.1 Downregulation and Myeloid Maturation Arrest Blood. 112: 845-845. DOI: 10.1182/Blood.V112.11.845.845 |
0.384 |
|
| 2008 |
List AF, Baer MR, Steensma D, Raza A, Esposito J, Virkus J, Paley C, Feigert J, Besa EC. Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS) Blood. 112: 634-634. DOI: 10.1182/Blood.V112.11.634.634 |
0.307 |
|
| 2008 |
Battiwalla M, Fu T, Knight RD, List AF. Impact of Age on Transfusion Independence Response, Survival, and Transformation to Acute Myeloid Leukemia in Patients with Deletion 5q: A Sub-Analysis of the MDS-003 Study Blood. 112: 5071-5071. DOI: 10.1182/Blood.V112.11.5071.5071 |
0.394 |
|
| 2008 |
Epling-Burnette PK, Painter JS, Lee H-, Park J, Clemente M, O’Keefe C, Wei T, Wei S, Maciejewski J, Loughran TP, Paquette R, List AF, Djeu JY. Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes Blood. 112: 4121-4121. DOI: 10.1182/Blood.V112.11.4121.4121 |
0.358 |
|
| 2008 |
Clemente M, Cazzolli H, Jankowska A, O’Keefe C, Serio B, Nyland S, Wlodarski M, Epling-Burnette P, Loughran T, List A, Paquette R, Maciejewski J. Permissive Conditions for Evolution of PNH Clones Are Characterized by Overproduction of IFN-γ by Clonal CD4 and CD8 T Cells, Fas-L by CTLs, and Promoted by Immunogenetic Background Blood. 112: 4116-4116. DOI: 10.1182/Blood.V112.11.4116.4116 |
0.34 |
|
| 2008 |
Sugimori C, Zou J, O’Keefe C, Clemente M, Wei T, Maciejewski J, Loughran TP, Paquette R, List AF, Epling-Burnette PK. Dysregulated Distribution of Naïve and Memory FoxP3 Positive Regulatory T-Cells Associated with Anemia in Myelodysplastic Syndrome (MDS) Blood. 112: 3654-3654. DOI: 10.1182/Blood.V112.11.3654.3654 |
0.31 |
|
| 2008 |
Kumar A, List AF, Mhaskar R, Djulbegovic B. Efficacy of Hypo-Methylating Agents in the Treatment of Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Blood. 112: 3632-3632. DOI: 10.1182/Blood.V112.11.3632.3632 |
0.334 |
|
| 2008 |
Seymour JF, Fenaux P, Silverman LB, Mufti GJ, Hellström-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL. Effects of Azacitidine (AZA) Vs Conventional Care Regimens (CCR) in Elderly (≥75 years) Patients (Pts) with Myelodysplastic Syndromes (MDS) from the AZA-001 Survival Trial Blood. 112: 3629-3629. DOI: 10.1182/Blood.V112.11.3629.3629 |
0.37 |
|
| 2008 |
Ravandi F, Sampath D, Plunkett W, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, Alvarez V, Becker MD, List AF, Sebti S, Kantarjian HM, Lancet J. Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy Blood. 112: 2987-2987. DOI: 10.1182/Blood.V112.11.2987.2987 |
0.391 |
|
| 2008 |
Feldman EJ, Lancet J, Kolitz JE, Ritchie E, List AF, Asatiani E, Curcio TJ, Burton M, Fricano M, Swenson C, Mayer LD, Louie AC. Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias Blood. 112: 2984-2984. DOI: 10.1182/Blood.V112.11.2984.2984 |
0.392 |
|
| 2008 |
Kang LC, Rocha K, Rollison DE, Moscinski LC, List AF. Expression of Cellular Senesence Associated B-Galactosidase (SABG) Is up-Regulated in Melodysplastic Syndrome Blood. 112: 2684-2684. DOI: 10.1182/Blood.V112.11.2684.2684 |
0.377 |
|
| 2008 |
Rollison DE, List AF, Lee J, Jonathan KA, Fulp W, Li X, Zheng W, Painter J, Park J, Epling-Burnette P. Short Telomere Length as a Risk Factor for Myelodysplastic Syndromes: A Case-Control Study Blood. 112: 2674-2674. DOI: 10.1182/Blood.V112.11.2674.2674 |
0.363 |
|
| 2008 |
Wetzstein GA, Lancet JE, Kallner JE, Sivik JM, Ho VQ, George TJ, Desai S, Fisher S, Newton MD, List AF. Safety, Feasibility, and Cost-Effectiveness with Outpatient Administration of High-Dose Cytarabine Consolidation in Acute Myeloid Leukemia Blood. 112: 2405-2405. DOI: 10.1182/Blood.V112.11.2405.2405 |
0.391 |
|
| 2008 |
Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, McKenzie D, Beach CL. The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS) Blood. 112: 227-227. DOI: 10.1182/Blood.V112.11.227.227 |
0.352 |
|
| 2008 |
Sekeres MA, List AF, Cuthbertson D, Paquette R, Latham D, Afable M, Paulic K, Loughran TP, Maciejewski JP. Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Blood. 112: 221-221. DOI: 10.1182/Blood.V112.11.221.221 |
0.376 |
|
| 2008 |
Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LB, List A, Gore SD, Seymour JF, Backstrom J, McKenzie D, Beach CL. Management and Supportive Care Measures of Adverse Events (AEs) in Higher-Risk MDS Patients (Pts) Treated with Azacitidine (AZA) Blood. 112: 1653-1653. DOI: 10.1182/Blood.V112.11.1653.1653 |
0.34 |
|
| 2007 |
Sokol L, List AF. Immunomodulatory therapy for myelodysplastic syndromes. International Journal of Hematology. 86: 301-5. PMID 18055335 DOI: 10.1532/Ijh97.06063 |
0.42 |
|
| Show low-probability matches. |